[
  {
    "symbol": "VERA",
    "timestamp": "2025-01-20 18:12:03",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 33.36,
    "priceChange": 1.77,
    "openPrice": 33.03,
    "prevClose": 32.78,
    "dayHigh": 34.33,
    "dayLow": 32.25,
    "volume": 1045400,
    "prevVolume": 719400,
    "averageVolume": 742085.5555555555,
    "volumeChange": 45.32,
    "volumeVsAvg": 40.87,
    "recentVolumes": [
      1422500,
      695700,
      977400,
      719400,
      1045400
    ],
    "marketCap": 2113091840,
    "fiftyTwoWeekHigh": 51.61,
    "fiftyTwoWeekLow": 16.38,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-14 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-reports-inducement-grants-210500844.html"
      },
      {
        "title": "Vera Therapeutics Acquires Global Rights to Dual BAFF/APRIL Inhibitor",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-13 09:32:28",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-acquires-global-rights-173228645.html"
      },
      {
        "title": "Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-acquires-global-rights-120000537.html"
      },
      {
        "title": "Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-07 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-participate-43rd-annual-210500861.html"
      },
      {
        "title": "Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 13:12:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vera-therapeutics-insider-sold-shares-211207472.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ANIX",
    "timestamp": "2025-01-20 18:12:03",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.41,
    "priceChange": -6.59,
    "openPrice": 2.59,
    "prevClose": 2.58,
    "dayHigh": 2.64,
    "dayLow": 2.36,
    "volume": 145200,
    "prevVolume": 188200,
    "averageVolume": 94648.88888888889,
    "volumeChange": -22.85,
    "volumeVsAvg": 53.41,
    "recentVolumes": [
      42900,
      126700,
      306900,
      188200,
      145200
    ],
    "marketCap": 77594528,
    "fiftyTwoWeekHigh": 5.0,
    "fiftyTwoWeekLow": 2.07,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Anixa Biosciences Leads 3 Promising Penny Stocks On US Exchanges",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-17 05:07:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-leads-3-promising-130759240.html"
      },
      {
        "title": "Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-14 02:07:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-nasdaq-anix-good-100720652.html"
      },
      {
        "title": "iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024",
        "publisher": "ACCESS Newswire",
        "timestamp": "2024-12-06 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/iaccess-alphas-buyside-best-ideas-133000682.html"
      },
      {
        "title": "Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-04 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-present-iaccess-alpha-133000322.html"
      },
      {
        "title": "Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Could Be 20% Below Their Intrinsic Value Estimate",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-04 03:17:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/anixa-biosciences-inc-nasdaq-anix-111717093.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "INMB",
    "timestamp": "2025-01-20 18:12:04",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 6.45,
    "priceChange": -4.02,
    "openPrice": 6.79,
    "prevClose": 6.72,
    "dayHigh": 6.8,
    "dayLow": 6.03,
    "volume": 380000,
    "prevVolume": 631500,
    "averageVolume": 283528.8888888889,
    "volumeChange": -39.83,
    "volumeVsAvg": 34.03,
    "recentVolumes": [
      1312000,
      603400,
      405100,
      631500,
      380000
    ],
    "marketCap": 143012624,
    "fiftyTwoWeekHigh": 14.74,
    "fiftyTwoWeekLow": 4.32,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Raymond James Predicts Up to ~930% Rally for These 2 \u2018Strong Buy\u2019 Stocks",
        "publisher": "TipRanks",
        "timestamp": "2025-01-12 03:05:24",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/raymond-james-predicts-930-rally-110524028.html"
      },
      {
        "title": "INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-10 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmune-bio-inc-completes-repayment-130000370.html"
      },
      {
        "title": "OmniScience and INmune Bio Partner for Alzheimer\u2019s Trial",
        "publisher": "Exec Edge",
        "timestamp": "2024-12-04 11:51:57",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/omniscience-inmune-bio-partner-alzheimer-195157692.html"
      },
      {
        "title": "INmune Bio Partners With OmniScience to Accelerate Alzheimer's Trial",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-04 08:06:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmune-bio-partners-omniscience-accelerate-160602564.html"
      },
      {
        "title": "OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer\u2019s Trial with Vivo, a Novel genAI Clinical Trial Control Tower",
        "publisher": "Business Wire",
        "timestamp": "2024-12-04 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/omniscience-inc-inmune-bio-inc-140000928.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GUTS",
    "timestamp": "2025-01-20 18:12:05",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.79,
    "priceChange": -1.1,
    "openPrice": 1.82,
    "prevClose": 1.81,
    "dayHigh": 1.86,
    "dayLow": 1.77,
    "volume": 236300,
    "prevVolume": 194100,
    "averageVolume": 354595.55555555556,
    "volumeChange": 21.74,
    "volumeVsAvg": -33.36,
    "recentVolumes": [
      1869800,
      499900,
      254900,
      194100,
      236300
    ],
    "marketCap": 86578016,
    "fiftyTwoWeekHigh": 14.5,
    "fiftyTwoWeekLow": 1.74,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-announces-positive-initial-120000372.html"
      },
      {
        "title": "Here\u2019s Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-06 06:10:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-fractyl-health-inc-nasdaq-141010336.html"
      },
      {
        "title": "Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva\u00ae Smart GLP-1\u2122 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-12 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-unveils-promising-preclinical-120000099.html"
      },
      {
        "title": "Fractyl Health to Present New Preclinical Data from its Rejuva\u00ae Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-09 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-present-preclinical-data-120000185.html"
      },
      {
        "title": "Fractyl Health to Participate in the Upcoming December Conferences",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-26 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fractyl-health-participate-upcoming-december-120000138.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MIRA",
    "timestamp": "2025-01-20 18:12:06",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 1.22,
    "priceChange": 1.25,
    "openPrice": 1.22,
    "prevClose": 1.2,
    "dayHigh": 1.25,
    "dayLow": 1.19,
    "volume": 181800,
    "prevVolume": 140400,
    "averageVolume": 1183171.111111111,
    "volumeChange": 29.49,
    "volumeVsAvg": -84.63,
    "recentVolumes": [
      353700,
      242900,
      160100,
      140400,
      181800
    ],
    "marketCap": 20038690,
    "fiftyTwoWeekHigh": 5.01,
    "fiftyTwoWeekLow": 0.51,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-05 05:16:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-why-were-not-too-131641039.html"
      },
      {
        "title": "Memecoin Degens Raise Millions for Rare Cancer Research After a Father\u2019s Plea",
        "publisher": "CoinDesk",
        "timestamp": "2024-12-26 23:56:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/e5512259-791e-34aa-b32a-0ed164bf7b78/memecoin-degens-raise.html"
      },
      {
        "title": "MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development",
        "publisher": "ACCESS Newswire",
        "timestamp": "2024-12-19 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mira-pharmaceuticals-submits-ind-ketamir-140000120.html"
      },
      {
        "title": "EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment",
        "publisher": "Benzinga",
        "timestamp": "2024-12-19 05:25:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-files-fda-132507382.html"
      },
      {
        "title": "MIRA Makes Major Strides",
        "publisher": "Zacks Small Cap Research",
        "timestamp": "2024-12-19 02:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mira-makes-major-strides-100500635.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "EYPT",
    "timestamp": "2025-01-20 18:12:06",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 7.49,
    "priceChange": 3.03,
    "openPrice": 7.36,
    "prevClose": 7.27,
    "dayHigh": 7.52,
    "dayLow": 7.15,
    "volume": 564900,
    "prevVolume": 1276600,
    "averageVolume": 871170.0,
    "volumeChange": -55.75,
    "volumeVsAvg": -35.16,
    "recentVolumes": [
      886600,
      806100,
      681000,
      1276600,
      564900
    ],
    "marketCap": 510517472,
    "fiftyTwoWeekHigh": 30.99,
    "fiftyTwoWeekLow": 6.9,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-16 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-pharmaceuticals-reports-inducement-grants-120000583.html"
      },
      {
        "title": "EyePoint Provides Company Update and Anticipated Development Milestones for 2025",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-provides-company-anticipated-development-120000764.html"
      },
      {
        "title": "EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-08 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-appoints-renowned-retina-specialist-120000534.html"
      },
      {
        "title": "Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-07 05:22:36",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/citigroup-initiates-eyepoint-pharmaceuticals-buy-132236187.html"
      },
      {
        "title": "EyePoint reports inducement grants under NASDAQ listing rule",
        "publisher": "TipRanks",
        "timestamp": "2024-12-17 04:25:29",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/eyepoint-reports-inducement-grants-under-122529566.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GNPX",
    "timestamp": "2025-01-20 18:12:07",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.73,
    "priceChange": 3.9,
    "openPrice": 0.73,
    "prevClose": 0.7,
    "dayHigh": 0.74,
    "dayLow": 0.7,
    "volume": 163000,
    "prevVolume": 169700,
    "averageVolume": 6955057.777777778,
    "volumeChange": -3.95,
    "volumeVsAvg": -97.66,
    "recentVolumes": [
      248700,
      324300,
      388400,
      169700,
      163000
    ],
    "marketCap": 6125810,
    "fiftyTwoWeekHigh": 13.0,
    "fiftyTwoWeekLow": 0.28,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Genprex Advances Cancer Trials and Diabetes Therapy",
        "publisher": "TipRanks",
        "timestamp": "2025-01-14 06:28:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-advances-cancer-trials-diabetes-142822795.html"
      },
      {
        "title": "Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-06 06:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-participate-43rd-annual-j-141500506.html"
      },
      {
        "title": "Genprex Completes Phase 1 Dose Escalation in Trial of Reqorsa Gene Therapy to Treat Lung Cancer",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-16 06:58:09",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-completes-phase-1-dose-145809723.html"
      },
      {
        "title": "Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa\u00ae Gene Therapy in Combination with Tecentriq\u00ae in Extensive Stage Small Cell Lung Cancer",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-16 06:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genprex-receives-safety-review-committee-141500271.html"
      },
      {
        "title": "Genprex links with University of Michigan on lung cancer treatment",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2024-11-21 07:16:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/95f14cf7-5e80-3c1a-84ed-c0e7c5289f76/genprex-links-with-university.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GLUE",
    "timestamp": "2025-01-20 18:12:07",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 5.66,
    "priceChange": -1.82,
    "openPrice": 5.79,
    "prevClose": 5.76,
    "dayHigh": 5.91,
    "dayLow": 5.56,
    "volume": 631100,
    "prevVolume": 1267300,
    "averageVolume": 2139838.888888889,
    "volumeChange": -50.2,
    "volumeVsAvg": -70.51,
    "recentVolumes": [
      998100,
      994100,
      1388400,
      1267300,
      631100
    ],
    "marketCap": 347424544,
    "fiftyTwoWeekHigh": 12.4,
    "fiftyTwoWeekLow": 3.21,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Monte Rosa Therapeutics provide corporate update, key milestones 2025",
        "publisher": "TipRanks",
        "timestamp": "2025-01-11 04:27:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monte-rosa-therapeutics-corporate-key-122726949.html"
      },
      {
        "title": "Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-10 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monte-rosa-therapeutics-provides-corporate-120000490.html"
      },
      {
        "title": "Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-06 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monte-rosa-therapeutics-present-43rd-120000102.html"
      },
      {
        "title": "Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-19 04:53:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wells-fargo-downgrades-monte-rosa-125311080.html"
      },
      {
        "title": "Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monte-rosa-therapeutics-appoints-dr-120000642.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TGTX",
    "timestamp": "2025-01-20 18:12:08",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 29.55,
    "priceChange": 1.41,
    "openPrice": 29.58,
    "prevClose": 29.14,
    "dayHigh": 29.68,
    "dayLow": 28.63,
    "volume": 2127300,
    "prevVolume": 1716300,
    "averageVolume": 3270904.4444444445,
    "volumeChange": 23.95,
    "volumeVsAvg": -34.96,
    "recentVolumes": [
      3862500,
      5637700,
      2985500,
      1716300,
      2127300
    ],
    "marketCap": 4599900160,
    "fiftyTwoWeekHigh": 36.84,
    "fiftyTwoWeekLow": 12.84,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Here\u2019s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX)",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-20 15:41:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-analysts-bullish-tg-therapeutics-234113754.html"
      },
      {
        "title": "Exploring Three High Growth Tech Stocks In The United States",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-15 10:03:15",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-three-high-growth-tech-180315578.html"
      },
      {
        "title": "Is TG Therapeutics Inc. (TGTX) Among Tuesday\u2019s Top Gainers?",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-15 07:29:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tg-therapeutics-inc-tgtx-among-152945528.html"
      },
      {
        "title": "TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 06:10:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tgtx-announces-2024-preliminary-results-141000241.html"
      },
      {
        "title": "TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 05:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tg-therapeutics-tgtx-moves-7-131500911.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "AUPH",
    "timestamp": "2025-01-20 18:12:09",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 8.02,
    "priceChange": 3.62,
    "openPrice": 7.81,
    "prevClose": 7.74,
    "dayHigh": 8.03,
    "dayLow": 7.67,
    "volume": 1596300,
    "prevVolume": 1048900,
    "averageVolume": 1292632.2222222222,
    "volumeChange": 52.19,
    "volumeVsAvg": 23.49,
    "recentVolumes": [
      2698900,
      1604300,
      1146300,
      1048900,
      1596300
    ],
    "marketCap": 1146863872,
    "fiftyTwoWeekHigh": 10.67,
    "fiftyTwoWeekLow": 4.71,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Exploring Three High Growth Tech Stocks In The United States",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-11 10:03:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-three-high-growth-tech-180300469.html"
      },
      {
        "title": "Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options",
        "publisher": "Zacks",
        "timestamp": "2024-12-10 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/implied-volatility-surging-aurinia-pharmaceuticals-133000514.html"
      },
      {
        "title": "Aurinia Pharmaceuticals Insider Bought Shares Worth $10,822,000, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-09 13:56:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aurinia-pharmaceuticals-insider-bought-shares-215653902.html"
      },
      {
        "title": "While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-06 06:54:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/while-institutions-own-40-aurinia-145408473.html"
      },
      {
        "title": "Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis",
        "publisher": "Business Wire",
        "timestamp": "2024-11-18 14:53:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aurinia-commends-2024-updated-acr-225300348.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ITCI",
    "timestamp": "2025-01-20 18:12:09",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 126.17,
    "priceChange": -0.07,
    "openPrice": 126.65,
    "prevClose": 126.26,
    "dayHigh": 126.74,
    "dayLow": 126.16,
    "volume": 6016600,
    "prevVolume": 7519100,
    "averageVolume": 1366405.5555555555,
    "volumeChange": -19.98,
    "volumeVsAvg": 340.32,
    "recentVolumes": [
      35895100,
      16589900,
      7741800,
      7519100,
      6016600
    ],
    "marketCap": 13407992832,
    "fiftyTwoWeekHigh": 128.0,
    "fiftyTwoWeekLow": 62.78,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week\u2019s Rally",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-19 10:00:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-intra-cellular-therapies-inc-180006888.html"
      },
      {
        "title": "Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): \u2018Intra-Cellular Had Something\u2019",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-18 18:42:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jim-cramer-intra-cellular-therapies-024242759.html"
      },
      {
        "title": "Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales",
        "publisher": "Zacks",
        "timestamp": "2025-01-17 12:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pharma-stock-roundup-j-js-200000018.html"
      },
      {
        "title": "J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns",
        "publisher": "GuruFocus.com",
        "timestamp": "2025-01-15 08:00:16",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/j-js-aaa-rating-jeopardy-160016510.html"
      },
      {
        "title": "J&J\u2019s Top Rating at Risk Because of Intra-Cellular Deal",
        "publisher": "Bloomberg",
        "timestamp": "2025-01-15 07:16:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/j-j-prime-rating-risk-200159925.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CLOV",
    "timestamp": "2025-01-20 18:12:10",
    "sector": "Healthcare",
    "industry": "Healthcare Plans",
    "price": 4.07,
    "priceChange": 0.0,
    "openPrice": 4.08,
    "prevClose": 4.07,
    "dayHigh": 4.13,
    "dayLow": 4.01,
    "volume": 5429100,
    "prevVolume": 7685200,
    "averageVolume": 6758260.0,
    "volumeChange": -29.36,
    "volumeVsAvg": -19.67,
    "recentVolumes": [
      11484300,
      7246900,
      8078800,
      7685200,
      5429100
    ],
    "marketCap": 2044524672,
    "fiftyTwoWeekHigh": 4.71,
    "fiftyTwoWeekLow": 0.61,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Clover Health Sees 27% Growth in Medicare Members",
        "publisher": "TipRanks",
        "timestamp": "2025-01-14 06:30:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/clover-health-sees-27-growth-143012699.html"
      },
      {
        "title": "Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/clover-health-reports-27-growth-140000713.html"
      },
      {
        "title": "Clover Health Investments Corp. (CLOV): This Small-Cap Stock Is Poised To Outperform in 2025",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-07 09:27:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/clover-health-investments-corp-clov-172752717.html"
      },
      {
        "title": "Counterpart Health Deploys Counterpart Assistant with Leading Accountable Care Organization",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-07 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/counterpart-health-deploys-counterpart-assistant-140000654.html"
      },
      {
        "title": "US Growth Companies With High Insider Ownership",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-01 07:08:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/us-growth-companies-high-insider-150810544.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "IPHA",
    "timestamp": "2025-01-20 18:12:13",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.7,
    "priceChange": 1.8,
    "openPrice": 1.72,
    "prevClose": 1.67,
    "dayHigh": 1.74,
    "dayLow": 1.69,
    "volume": 13700,
    "prevVolume": 31500,
    "averageVolume": 341658.8888888889,
    "volumeChange": -56.51,
    "volumeVsAvg": -95.99,
    "recentVolumes": [
      29600,
      12200,
      100200,
      31500,
      13700
    ],
    "marketCap": 150127600,
    "fiftyTwoWeekHigh": 3.51,
    "fiftyTwoWeekLow": 1.29,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024",
        "publisher": "Business Wire",
        "timestamp": "2025-01-15 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/number-shares-voting-rights-innate-060000066.html"
      },
      {
        "title": "Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 01:39:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/innate-pharma-focus-nk-cell-093955299.html"
      },
      {
        "title": "Innate Pharma Announces Transformative Strategy to Accelerate Growth",
        "publisher": "Business Wire",
        "timestamp": "2025-01-09 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/innate-pharma-announces-transformative-strategy-060000976.html"
      },
      {
        "title": "Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-12-19 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/innate-pharma-participate-43rd-annual-060000383.html"
      },
      {
        "title": "3 Promising Penny Stocks With Market Caps Under US$300M",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-11 18:07:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/3-promising-penny-stocks-market-020722794.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MDWD",
    "timestamp": "2025-01-20 18:12:14",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 17.62,
    "priceChange": -2.97,
    "openPrice": 18.16,
    "prevClose": 18.16,
    "dayHigh": 18.16,
    "dayLow": 17.5,
    "volume": 68600,
    "prevVolume": 81200,
    "averageVolume": 50082.22222222222,
    "volumeChange": -15.52,
    "volumeVsAvg": 36.97,
    "recentVolumes": [
      95500,
      121400,
      92200,
      81200,
      68600
    ],
    "marketCap": 190335600,
    "fiftyTwoWeekHigh": 24.0,
    "fiftyTwoWeekLow": 11.04,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions",
        "publisher": "TipRanks",
        "timestamp": "2025-01-09 05:28:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwound-advances-enzymatic-therapeutics-strategic-132820628.html"
      },
      {
        "title": "We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-24 03:08:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/were-keeping-eye-mediwounds-nasdaq-110855580.html"
      },
      {
        "title": "MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx\u00ae Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-17 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwound-host-virtual-key-opinion-130000986.html"
      },
      {
        "title": "MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company\u2019s Future",
        "publisher": "TipRanks",
        "timestamp": "2024-12-17 04:27:27",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwound-executives-acquire-18-462-122727456.html"
      },
      {
        "title": "MediWound Third Quarter 2024 Earnings: Misses Expectations",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-27 02:21:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mediwound-third-quarter-2024-earnings-102107305.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ZYME",
    "timestamp": "2025-01-20 18:12:14",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 13.88,
    "priceChange": -0.79,
    "openPrice": 14.11,
    "prevClose": 13.99,
    "dayHigh": 14.13,
    "dayLow": 13.58,
    "volume": 323800,
    "prevVolume": 513600,
    "averageVolume": 545701.1111111111,
    "volumeChange": -36.95,
    "volumeVsAvg": -40.66,
    "recentVolumes": [
      765200,
      360900,
      384000,
      513600,
      323800
    ],
    "marketCap": 956019776,
    "fiftyTwoWeekHigh": 17.7,
    "fiftyTwoWeekLow": 7.97,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-08 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-outlines-strategic-priorities-outlook-210500719.html"
      },
      {
        "title": "Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-13 04:12:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-nasdaq-zyme-good-position-121249503.html"
      },
      {
        "title": "Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-12 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-hosts-r-d-day-133000016.html"
      },
      {
        "title": "Zymeworks Announces Participation in Upcoming Investor Conferences",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-21 03:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zymeworks-announces-participation-upcoming-investor-110500883.html"
      },
      {
        "title": "FDA Grants U.S. Approval of Ziihera\u00ae (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-21 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/fda-grants-u-approval-ziihera-110000775.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ASMB",
    "timestamp": "2025-01-20 18:12:15",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 14.5,
    "priceChange": 0.55,
    "openPrice": 14.46,
    "prevClose": 14.42,
    "dayHigh": 14.53,
    "dayLow": 14.15,
    "volume": 15000,
    "prevVolume": 16200,
    "averageVolume": 34524.444444444445,
    "volumeChange": -7.41,
    "volumeVsAvg": -56.55,
    "recentVolumes": [
      23300,
      27100,
      49000,
      16200,
      15000
    ],
    "marketCap": 92102640,
    "fiftyTwoWeekHigh": 19.93,
    "fiftyTwoWeekLow": 9.84,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Gilead Buys $20.1 Million of Assembly Biosciences Stock",
        "publisher": "Barrons.com",
        "timestamp": "2024-12-29 00:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/14ddabf4-3145-39bb-b7ee-c8c9e0c005b7/gilead-buys-%2420.1-million-of.html"
      },
      {
        "title": "Sector Update: Health Care",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-26 12:29:23",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sector-health-care-202923116.html"
      },
      {
        "title": "Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-26 05:37:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assembly-biosciences-says-antiviral-drug-133739051.html"
      },
      {
        "title": "Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-26 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assembly-biosciences-reports-interim-phase-130000953.html"
      },
      {
        "title": "Assembly Biosciences Says It Will Receive $30.1 Million Funding From Gilead Sciences",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-19 06:21:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assembly-biosciences-says-receive-30-142126140.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "JAZZ",
    "timestamp": "2025-01-20 18:12:16",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 121.2,
    "priceChange": -1.16,
    "openPrice": 122.52,
    "prevClose": 122.62,
    "dayHigh": 122.78,
    "dayLow": 120.79,
    "volume": 388500,
    "prevVolume": 357300,
    "averageVolume": 601563.3333333334,
    "volumeChange": 8.73,
    "volumeVsAvg": -35.42,
    "recentVolumes": [
      569600,
      502700,
      402400,
      357300,
      388500
    ],
    "marketCap": 7325888512,
    "fiftyTwoWeekHigh": 134.17,
    "fiftyTwoWeekLow": 99.06,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2025-01-15 10:57:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/2af4c28e-7735-3c99-9f74-03311daf268c/jp-morgan-2025%3A-jazz.html"
      },
      {
        "title": "Jazz Pharmaceuticals plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-15 10:54:09",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-pharmaceuticals-plc-jazz-analysts-185409426.html"
      },
      {
        "title": "Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-17 13:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-pharmaceuticals-present-43rd-annual-211500924.html"
      },
      {
        "title": "Jazz Pharmaceuticals CEO Bruce Cozadd Plans to Retire",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-16 13:42:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-pharmaceuticals-ceo-bruce-cozadd-214249417.html"
      },
      {
        "title": "Jazz Pharmaceuticals Announces CEO Succession Plan",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-16 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jazz-pharmaceuticals-announces-ceo-succession-210500147.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "PRTA",
    "timestamp": "2025-01-20 18:12:16",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 13.77,
    "priceChange": 4.48,
    "openPrice": 13.33,
    "prevClose": 13.18,
    "dayHigh": 14.38,
    "dayLow": 13.0,
    "volume": 543600,
    "prevVolume": 302500,
    "averageVolume": 571362.2222222222,
    "volumeChange": 79.7,
    "volumeVsAvg": -4.86,
    "recentVolumes": [
      390300,
      616800,
      332800,
      302500,
      543600
    ],
    "marketCap": 740945792,
    "fiftyTwoWeekHigh": 34.65,
    "fiftyTwoWeekLow": 11.7,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Prothena Announces Board of Directors Update",
        "publisher": "Business Wire",
        "timestamp": "2024-12-30 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/prothena-announces-board-directors-210500095.html"
      },
      {
        "title": "We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-25 05:06:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/were-not-very-worried-prothenas-130656724.html"
      },
      {
        "title": "Chardan Initiates Coverage on Prothena With Buy Rating, $40 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 05:17:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chardan-initiates-coverage-prothena-buy-131743623.html"
      },
      {
        "title": "Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-12-19 13:22:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/180869c4-7f07-3b44-b8f5-6b328599d8b1/prothena-catapults%2C-flashing.html"
      },
      {
        "title": "Prothena\u2019s Parkinson\u2019s study fails primary endpoint despite some success",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2024-12-19 05:09:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/10ea6454-3c76-3514-b537-c94532af3cdb/prothena%E2%80%99s-parkinson%E2%80%99s-study.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TMDX",
    "timestamp": "2025-01-20 18:12:17",
    "sector": "Healthcare",
    "industry": "Medical Devices",
    "price": 57.13,
    "priceChange": -1.53,
    "openPrice": 58.38,
    "prevClose": 58.02,
    "dayHigh": 58.85,
    "dayLow": 56.03,
    "volume": 2669100,
    "prevVolume": 2213300,
    "averageVolume": 1935060.0,
    "volumeChange": 20.59,
    "volumeVsAvg": 37.93,
    "recentVolumes": [
      6201000,
      2828900,
      2327900,
      2213300,
      2669100
    ],
    "marketCap": 1919717888,
    "fiftyTwoWeekHigh": 177.37,
    "fiftyTwoWeekLow": 56.03,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "TMDX Stock Down Despite Responding to Misleading Short-Seller Report",
        "publisher": "Zacks",
        "timestamp": "2025-01-20 08:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/tmdx-stock-down-despite-responding-160000963.html"
      },
      {
        "title": "Why TransMedics Fell 15.7% This Week",
        "publisher": "Motley Fool",
        "timestamp": "2025-01-17 06:22:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/e2df1a27-e4f1-3b64-9d27-7cc01a5f3472/why-transmedics-fell-15.7%25.html"
      },
      {
        "title": "Transmedics (TMDX) Fell on Investors\u2019 Growing Concerns",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-17 05:07:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/transmedics-tmdx-fell-investors-growing-130711534.html"
      },
      {
        "title": "TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/transmedics-responds-inaccurate-misleading-claims-120000397.html"
      },
      {
        "title": "Scorpion Capital shorts TransMedics, alleging fraud in report",
        "publisher": "Yahoo Finance Video",
        "timestamp": "2025-01-10 13:16:00",
        "type": "VIDEO",
        "url": "https://finance.yahoo.com/video/scorpion-capital-shorts-transmedics-alleging-211600842.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GILD",
    "timestamp": "2025-01-20 18:12:18",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 91.83,
    "priceChange": 0.2,
    "openPrice": 92.0,
    "prevClose": 91.65,
    "dayHigh": 92.8,
    "dayLow": 91.68,
    "volume": 6852100,
    "prevVolume": 8955300,
    "averageVolume": 6791998.888888889,
    "volumeChange": -23.49,
    "volumeVsAvg": 0.88,
    "recentVolumes": [
      6523300,
      7418300,
      8084400,
      8955300,
      6852100
    ],
    "marketCap": 114457427968,
    "fiftyTwoWeekHigh": 98.9,
    "fiftyTwoWeekLow": 62.07,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Can Gilead Sciences Sustain Its Growth Momentum in 2025?",
        "publisher": "Zacks",
        "timestamp": "2025-01-20 11:02:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gilead-sciences-sustain-growth-momentum-190200822.html"
      },
      {
        "title": "House of the Week: A Riverfront Retreat in Southeastern Connecticut",
        "publisher": "The Wall Street Journal",
        "timestamp": "2025-01-17 12:25:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/025949a6-d21b-353c-ab0e-01614b50e662/house-of-the-week%3A-a.html"
      },
      {
        "title": "The Zacks Analyst Blog Salesforce, Shell and Gilead  Sciences",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 23:17:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zacks-analyst-blog-salesforce-shell-071700741.html"
      },
      {
        "title": "Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 13:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/top-stock-reports-salesforce-shell-210000021.html"
      },
      {
        "title": "Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-16 10:12:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gilead-sciences-gild-among-best-181238825.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NTNX",
    "timestamp": "2025-01-20 18:12:18",
    "sector": "Technology",
    "industry": "Software - Infrastructure",
    "price": 65.19,
    "priceChange": -2.04,
    "openPrice": 66.65,
    "prevClose": 66.55,
    "dayHigh": 66.9,
    "dayLow": 65.06,
    "volume": 1613600,
    "prevVolume": 1949900,
    "averageVolume": 2314513.3333333335,
    "volumeChange": -17.25,
    "volumeVsAvg": -30.28,
    "recentVolumes": [
      1786100,
      2006800,
      2307800,
      1949900,
      1613600
    ],
    "marketCap": 17452830720,
    "fiftyTwoWeekHigh": 75.8,
    "fiftyTwoWeekLow": 43.35,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "How to Find Strong Computer and Technology Stocks Slated for Positive Earnings Surprises",
        "publisher": "Zacks",
        "timestamp": "2025-01-20 06:00:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/strong-computer-technology-stocks-slated-140013371.html"
      },
      {
        "title": "Does Nutanix (NTNX) Have the Potential to Rally 25.47% as Wall Street Analysts Expect?",
        "publisher": "Zacks",
        "timestamp": "2025-01-17 06:55:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/does-nutanix-ntnx-potential-rally-145507891.html"
      },
      {
        "title": "Is Nutanix (NTNX) a Buy as Wall Street Analysts Look Optimistic?",
        "publisher": "Zacks",
        "timestamp": "2025-01-17 06:30:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/nutanix-ntnx-buy-wall-street-143014385.html"
      },
      {
        "title": "NTNX Gains 25% in 6 Months: Here's Why You Should Hold on to the Stock",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 08:04:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ntnx-gains-25-6-months-160400057.html"
      },
      {
        "title": "Nutanix (NTNX) Exceeds Market Returns: Some Facts to Consider",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 14:50:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/nutanix-ntnx-exceeds-market-returns-225022360.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "INAB",
    "timestamp": "2025-01-20 18:12:19",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.3,
    "priceChange": -0.27,
    "openPrice": 0.29,
    "prevClose": 0.3,
    "dayHigh": 0.31,
    "dayLow": 0.27,
    "volume": 407000,
    "prevVolume": 400500,
    "averageVolume": 1056761.111111111,
    "volumeChange": 1.62,
    "volumeVsAvg": -61.49,
    "recentVolumes": [
      1341800,
      750200,
      685400,
      400500,
      407000
    ],
    "marketCap": 21469552,
    "fiftyTwoWeekHigh": 1.74,
    "fiftyTwoWeekLow": 0.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "IN8bio to Present at Biotech Showcase 2025 in San Francisco",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-06 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/in8bio-present-biotech-showcase-2025-120000435.html"
      },
      {
        "title": "IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-10 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/in8bio-reports-continued-progression-free-120000400.html"
      },
      {
        "title": "IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-02 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/in8bio-present-noble-capital-markets-120000926.html"
      },
      {
        "title": "IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-25 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/in8bio-reports-continued-durable-remissions-120000298.html"
      },
      {
        "title": "INAB: Upcoming Presentations at SNO & ASH",
        "publisher": "Zacks Small Cap Research",
        "timestamp": "2024-11-14 07:14:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inab-upcoming-presentations-sno-ash-151400737.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MNPR",
    "timestamp": "2025-01-20 18:12:20",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 28.53,
    "priceChange": -6.4,
    "openPrice": 31.3,
    "prevClose": 30.48,
    "dayHigh": 31.95,
    "dayLow": 26.67,
    "volume": 68500,
    "prevVolume": 64100,
    "averageVolume": 914288.8888888889,
    "volumeChange": 6.86,
    "volumeVsAvg": -92.51,
    "recentVolumes": [
      37200,
      54100,
      104100,
      64100,
      68500
    ],
    "marketCap": 174166208,
    "fiftyTwoWeekHigh": 38.5,
    "fiftyTwoWeekLow": 1.54,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Piper Sandler Initiates Monopar Therapeutics at Overweight With $72 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 07:37:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/piper-sandler-initiates-monopar-therapeutics-153700282.html"
      },
      {
        "title": "MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN",
        "publisher": "Zacks",
        "timestamp": "2025-01-02 07:02:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mnpr-stock-skyrockets-384-3-150200991.html"
      },
      {
        "title": "These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year \u2014 Here\u2019s What Analysts Expect in 2025",
        "publisher": "TipRanks",
        "timestamp": "2024-12-30 23:36:34",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/2-monster-growth-stocks-skyrocketed-073634714.html"
      },
      {
        "title": "What Awaits These 4 Biotech Stocks That More Than Doubled in 2024",
        "publisher": "Zacks",
        "timestamp": "2024-12-26 07:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/awaits-4-biotech-stocks-more-152900258.html"
      },
      {
        "title": "Monopar Therapeutics Prices $40 Million Offering, Private Placement",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 07:44:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/monopar-therapeutics-prices-40-million-154443346.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "APVO",
    "timestamp": "2025-01-20 18:12:20",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 4.64,
    "priceChange": 2.88,
    "openPrice": 4.44,
    "prevClose": 4.51,
    "dayHigh": 4.74,
    "dayLow": 4.38,
    "volume": 43100,
    "prevVolume": 41300,
    "averageVolume": 253182.44444444444,
    "volumeChange": 4.36,
    "volumeVsAvg": -82.98,
    "recentVolumes": [
      68000,
      16600,
      61400,
      41300,
      43100
    ],
    "marketCap": 6504642,
    "fiftyTwoWeekHigh": 399.6,
    "fiftyTwoWeekLow": 3.65,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Aptevo's Peter Pavlik, PhD, Chairing Session on \"Bi and Multispecific Biologics\" at Cambridge Healthcare Institute's Pep Talk 2025",
        "publisher": "ACCESS Newswire",
        "timestamp": "2025-01-15 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aptevos-peter-pavlik-phd-chairing-130000329.html"
      },
      {
        "title": "Aptevo Therapeutics Announces Exercise of Warrants for  $6.2 Million Gross Proceeds",
        "publisher": "ACCESS Newswire",
        "timestamp": "2024-12-12 09:50:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aptevo-therapeutics-announces-exercise-warrants-175000415.html"
      },
      {
        "title": "100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial",
        "publisher": "ACCESS Newswire",
        "timestamp": "2024-12-12 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/100-patients-achieve-remission-within-140000631.html"
      },
      {
        "title": "Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects",
        "publisher": "ACCESS Newswire",
        "timestamp": "2024-12-04 05:35:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bispecific-antibody-apvo442-differentiated-treat-133500711.html"
      },
      {
        "title": "Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan",
        "publisher": "ACCESS Newswire",
        "timestamp": "2024-11-29 06:55:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/aptevo-therapeutics-announces-1-37-145500304.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "HRMY",
    "timestamp": "2025-01-20 18:12:21",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 39.04,
    "priceChange": 1.3,
    "openPrice": 38.61,
    "prevClose": 38.54,
    "dayHigh": 39.54,
    "dayLow": 38.51,
    "volume": 658900,
    "prevVolume": 1064600,
    "averageVolume": 701887.7777777778,
    "volumeChange": -38.11,
    "volumeVsAvg": -6.12,
    "recentVolumes": [
      794800,
      429600,
      454000,
      1064600,
      658900
    ],
    "marketCap": 2227072256,
    "fiftyTwoWeekHigh": 41.61,
    "fiftyTwoWeekLow": 28.14,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Should Value Investors Buy Harmony Biosciences (HRMY) Stock?",
        "publisher": "Zacks",
        "timestamp": "2025-01-20 06:40:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/value-investors-buy-harmony-biosciences-144021277.html"
      },
      {
        "title": "Why Harmony Biosciences (HRMY) Might be Well Poised for a Surge",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 09:20:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-harmony-biosciences-hrmy-might-172006100.html"
      },
      {
        "title": "How Much Upside is Left in Harmony Biosciences (HRMY)? Wall Street Analysts Think 39.48%",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 06:55:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/much-upside-left-harmony-biosciences-145512491.html"
      },
      {
        "title": "Harmony Biosciences price target raised to $32 from $31 at BofA",
        "publisher": "TipRanks",
        "timestamp": "2025-01-15 05:11:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/harmony-biosciences-price-target-raised-131114209.html"
      },
      {
        "title": "HRMY or RGEN: Which Is the Better Value Stock Right Now?",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 08:40:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/hrmy-rgen-better-value-stock-164012187.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BHC",
    "timestamp": "2025-01-20 18:12:21",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 7.43,
    "priceChange": -2.81,
    "openPrice": 7.5,
    "prevClose": 7.65,
    "dayHigh": 7.67,
    "dayLow": 7.43,
    "volume": 3766800,
    "prevVolume": 983100,
    "averageVolume": 1806645.5555555555,
    "volumeChange": 283.16,
    "volumeVsAvg": 108.5,
    "recentVolumes": [
      2816500,
      3451300,
      1376000,
      983100,
      3766800
    ],
    "marketCap": 2748879104,
    "fiftyTwoWeekHigh": 11.46,
    "fiftyTwoWeekLow": 3.96,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",
        "publisher": "TipRanks",
        "timestamp": "2025-01-18 05:20:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ozempic-xtandi-among-next-15-132048211.html"
      },
      {
        "title": "RBC on FDA's Third Tentative Approval For Rifaximin 550mg to Amneal Pharmaceuticals",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-17 10:03:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-fda-apos-third-tentative-180320321.html"
      },
      {
        "title": "Bausch Health's Xifaxan Selected for Medicare Drug Price Negotiations",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-17 09:14:34",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bausch-health-apos-xifaxan-selected-171434612.html"
      },
      {
        "title": "Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-17 07:27:25",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bausch-health-notes-xifaxan-550-152725266.html"
      },
      {
        "title": "Bausch Health Statement on Selection of XIFAXAN(R)\u202f(rifaximin) for Inflation Reduction Act's Medicare Negotiation Program",
        "publisher": "ACCESS Newswire",
        "timestamp": "2025-01-17 06:25:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bausch-health-statement-selection-xifaxan-142500457.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BCRX",
    "timestamp": "2025-01-20 18:12:22",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 7.45,
    "priceChange": 5.52,
    "openPrice": 7.04,
    "prevClose": 7.06,
    "dayHigh": 7.49,
    "dayLow": 6.96,
    "volume": 3963000,
    "prevVolume": 2519100,
    "averageVolume": 2011862.2222222222,
    "volumeChange": 57.32,
    "volumeVsAvg": 96.98,
    "recentVolumes": [
      2690600,
      2528900,
      2365600,
      2519100,
      3963000
    ],
    "marketCap": 1543140736,
    "fiftyTwoWeekHigh": 8.88,
    "fiftyTwoWeekLow": 4.03,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "BioCryst price target raised to $12 from $10 at Evercore ISI",
        "publisher": "TipRanks",
        "timestamp": "2025-01-14 05:35:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-price-target-raised-12-133549044.html"
      },
      {
        "title": "Exploring High Growth Tech Stocks In January 2025",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-10 10:06:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-180659145.html"
      },
      {
        "title": "BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 07:02:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-pharmaceuticals-preliminary-q4-revenue-150255115.html"
      },
      {
        "title": "BioCryst Announces Preliminary Full Year 2024 ORLADEYO\u00ae (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-10 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-announces-preliminary-full-2024-120000323.html"
      },
      {
        "title": "BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-07 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biocryst-present-43rd-annual-j-120000310.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GRTX",
    "timestamp": "2025-01-20 18:12:23",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.04,
    "priceChange": -0.89,
    "openPrice": 0.04,
    "prevClose": 0.05,
    "dayHigh": 0.05,
    "dayLow": 0.04,
    "volume": 3700,
    "prevVolume": 1100,
    "averageVolume": 221981.11111111112,
    "volumeChange": 236.36,
    "volumeVsAvg": -98.33,
    "recentVolumes": [
      90400,
      76700,
      142600,
      1100,
      3700
    ],
    "marketCap": 2447649,
    "fiftyTwoWeekHigh": 0.29,
    "fiftyTwoWeekLow": 0.02,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Galera Therapeutics completes acquisition of Nova Pharmaceuticals",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-31 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galera-therapeutics-completes-acquisition-nova-120000107.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "AXSM",
    "timestamp": "2025-01-20 18:12:23",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 91.88,
    "priceChange": -1.93,
    "openPrice": 94.02,
    "prevClose": 93.69,
    "dayHigh": 94.71,
    "dayLow": 91.81,
    "volume": 808400,
    "prevVolume": 1162800,
    "averageVolume": 582918.8888888889,
    "volumeChange": -30.48,
    "volumeVsAvg": 38.68,
    "recentVolumes": [
      1879100,
      772400,
      1149200,
      1162800,
      808400
    ],
    "marketCap": 4455390720,
    "fiftyTwoWeekHigh": 105.0,
    "fiftyTwoWeekLow": 64.11,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-13 13:15:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/69134bb1-3490-34db-9e6a-94be6e5ab421/bridgebio%2C-ars-pharma%2C.html"
      },
      {
        "title": "Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axsome-therapeutics-provides-preliminary-fourth-120000827.html"
      },
      {
        "title": "Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-06 05:21:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axsome-therapeutics-inc-nasdaq-axsm-132103510.html"
      },
      {
        "title": "Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results",
        "publisher": "Benzinga",
        "timestamp": "2024-12-31 05:15:46",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axsome-reveals-data-alzheimers-studies-131546623.html"
      },
      {
        "title": "Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation",
        "publisher": "Investor's Business Daily",
        "timestamp": "2024-12-30 14:07:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/8b9c708e-afc4-3e18-8501-f910a981fb1c/axsome-flashes-a-bearish.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SMMT",
    "timestamp": "2025-01-20 18:12:24",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 19.03,
    "priceChange": 4.62,
    "openPrice": 18.52,
    "prevClose": 18.19,
    "dayHigh": 19.39,
    "dayLow": 18.33,
    "volume": 2586200,
    "prevVolume": 2136500,
    "averageVolume": 3831311.111111111,
    "volumeChange": 21.05,
    "volumeVsAvg": -32.5,
    "recentVolumes": [
      1783700,
      3256900,
      2569200,
      2136500,
      2586200
    ],
    "marketCap": 14033636352,
    "fiftyTwoWeekHigh": 33.89,
    "fiftyTwoWeekLow": 2.1,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Here\u2019s Why Analysts Are Bullish on Summit Therapeutics Inc. (SMMT)",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-20 16:00:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-analysts-bullish-summit-therapeutics-000017544.html"
      },
      {
        "title": "Is Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts?",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-18 14:52:30",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/summit-therapeutics-smmt-best-russell-225230368.html"
      },
      {
        "title": "Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "Business Wire",
        "timestamp": "2025-01-16 13:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/summit-therapeutics-reports-inducement-grants-211500809.html"
      },
      {
        "title": "Why Summit Therapeutics Rocketed 584% in 2024",
        "publisher": "Motley Fool",
        "timestamp": "2025-01-15 06:35:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/7e589637-cc82-3fa8-8971-1808e0e90116/why-summit-therapeutics.html"
      },
      {
        "title": "Truist Initiates Summit Therapeutics at Buy With $35 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-08 03:31:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/truist-initiates-summit-therapeutics-buy-113142362.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SAGE",
    "timestamp": "2025-01-20 18:12:24",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 7.07,
    "priceChange": 1.43,
    "openPrice": 7.02,
    "prevClose": 6.97,
    "dayHigh": 7.19,
    "dayLow": 6.88,
    "volume": 4917700,
    "prevVolume": 6054500,
    "averageVolume": 1236550.0,
    "volumeChange": -18.78,
    "volumeVsAvg": 297.7,
    "recentVolumes": [
      12091000,
      4004000,
      4397200,
      6054500,
      4917700
    ],
    "marketCap": 433106944,
    "fiftyTwoWeekHigh": 27.68,
    "fiftyTwoWeekLow": 4.62,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "The Zacks Analyst Blog Moderna, Regeneron, Intellia  Sage and GSK",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 23:12:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zacks-analyst-blog-moderna-regeneron-071200631.html"
      },
      {
        "title": "Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist",
        "publisher": "TipRanks",
        "timestamp": "2025-01-14 06:41:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sage-therapeutics-takeover-bid-undervalues-144112036.html"
      },
      {
        "title": "Biogen bid for Sage does not change narrative, says BMO Capital",
        "publisher": "TipRanks",
        "timestamp": "2025-01-14 06:40:30",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biogen-bid-sage-does-not-144030713.html"
      },
      {
        "title": "Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 06:03:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sage-therapeutics-sage-moves-35-140300773.html"
      },
      {
        "title": "Biogen proposes acquisition of partner Sage Therapeutics",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2025-01-13 12:12:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/2b588b3f-f7db-3d71-b9b2-c556eb55b4d6/biogen-proposes-acquisition.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MYNZ",
    "timestamp": "2025-01-20 18:12:25",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 4.69,
    "priceChange": 0.86,
    "openPrice": 4.87,
    "prevClose": 4.65,
    "dayHigh": 4.87,
    "dayLow": 4.45,
    "volume": 42600,
    "prevVolume": 95900,
    "averageVolume": 2482893.3333333335,
    "volumeChange": -55.58,
    "volumeVsAvg": -98.28,
    "recentVolumes": [
      114900,
      78200,
      206400,
      95900,
      42600
    ],
    "marketCap": 10730328,
    "fiftyTwoWeekHigh": 7.95,
    "fiftyTwoWeekLow": 0.18,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Mainz Biomed partners with Quest for colorectal cancer screening test",
        "publisher": "Medical Device Network",
        "timestamp": "2024-12-20 07:31:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/b14824ee-a88b-35e1-9d0d-8c08d200ed3e/mainz-biomed-partners-with.html"
      },
      {
        "title": "Mainz Biomed Partners With Quest Diagnostics for Colorectal Cancer Screening Test",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-19 06:12:37",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-partners-quest-diagnostics-141237446.html"
      },
      {
        "title": "Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-19 05:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-forms-agreement-quest-130100081.html"
      },
      {
        "title": "Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-16 14:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-announces-closing-8-220000766.html"
      },
      {
        "title": "Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-12 17:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mainz-biomed-announces-pricing-8-010000208.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GMAB",
    "timestamp": "2025-01-20 18:12:26",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 20.82,
    "priceChange": -1.89,
    "openPrice": 20.85,
    "prevClose": 21.22,
    "dayHigh": 21.02,
    "dayLow": 20.76,
    "volume": 1120100,
    "prevVolume": 2663000,
    "averageVolume": 1141920.0,
    "volumeChange": -57.94,
    "volumeVsAvg": -1.91,
    "recentVolumes": [
      955000,
      1003200,
      1838300,
      2663000,
      1120100
    ],
    "marketCap": 13239636992,
    "fiftyTwoWeekHigh": 31.88,
    "fiftyTwoWeekLow": 19.85,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "GMAB vs. QGEN: Which Stock Is the Better Value Option?",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 08:40:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gmab-vs-qgen-stock-better-164008274.html"
      },
      {
        "title": "Genmab (GMAB) Upgraded to Buy: Here's What You Should Know",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 09:00:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genmab-gmab-upgraded-buy-heres-170012618.html"
      },
      {
        "title": "Are Investors Undervaluing Genmab (GMAB) Right Now?",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 06:40:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/investors-undervaluing-genmab-gmab-now-144018972.html"
      },
      {
        "title": "High Growth Tech Stocks To Watch In January 2025",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-06 17:04:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-010418446.html"
      },
      {
        "title": "Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-03 10:56:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/genmab-present-43rd-annual-j-185600734.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NEO",
    "timestamp": "2025-01-20 18:12:26",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 14.2,
    "priceChange": 1.57,
    "openPrice": 14.02,
    "prevClose": 13.98,
    "dayHigh": 14.57,
    "dayLow": 14.01,
    "volume": 1279700,
    "prevVolume": 1046200,
    "averageVolume": 851947.7777777778,
    "volumeChange": 22.32,
    "volumeVsAvg": 50.21,
    "recentVolumes": [
      3528300,
      2618800,
      2211900,
      1046200,
      1279700
    ],
    "marketCap": 1824009856,
    "fiftyTwoWeekHigh": 19.11,
    "fiftyTwoWeekLow": 12.13,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-15 13:24:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/54e23201-f5bd-3284-9194-fd1a0bfaad81/neogenomics-is-on-the.html"
      },
      {
        "title": "NeoGenomics Provides 2025 Revenue Outlook",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-15 04:43:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/neogenomics-provides-2025-revenue-outlook-124326993.html"
      },
      {
        "title": "NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan",
        "publisher": "Business Wire",
        "timestamp": "2025-01-15 04:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/neogenomics-provides-2025-financial-guidance-120500098.html"
      },
      {
        "title": "NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 01:53:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/neogenomics-neo-surges-9-1-095300549.html"
      },
      {
        "title": "Adaptive Biotechnologies, NeoGenomics to Support Minimal Residual Disease Monitoring Options for Blood Cancer Patients",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-14 05:59:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adaptive-biotechnologies-neogenomics-support-minimal-135944400.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ARCT",
    "timestamp": "2025-01-20 18:12:27",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 16.76,
    "priceChange": -1.47,
    "openPrice": 17.32,
    "prevClose": 17.01,
    "dayHigh": 17.51,
    "dayLow": 16.69,
    "volume": 225200,
    "prevVolume": 230600,
    "averageVolume": 393191.1111111111,
    "volumeChange": -2.34,
    "volumeVsAvg": -42.73,
    "recentVolumes": [
      393900,
      270000,
      280100,
      230600,
      225200
    ],
    "marketCap": 454797472,
    "fiftyTwoWeekHigh": 45.0,
    "fiftyTwoWeekLow": 14.3,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Arcturus Therapeutics launches Phase I Avian Influenza trials in US",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2025-01-10 08:14:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/73b65936-cb90-3138-b27f-21310a44e59d/arcturus-therapeutics.html"
      },
      {
        "title": "Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial",
        "publisher": "Business Wire",
        "timestamp": "2025-01-10 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcturus-therapeutics-announces-initiation-phase-130000469.html"
      },
      {
        "title": "Arcturus Starts Dosing in Phase 2 Cystic Fibrosis, Ornithine Transcarbamylase Deficiency Treatment Studies",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-06 13:26:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcturus-starts-dosing-phase-2-212612141.html"
      },
      {
        "title": "Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency",
        "publisher": "Business Wire",
        "timestamp": "2025-01-06 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcturus-therapeutics-announces-initiation-dosing-210100304.html"
      },
      {
        "title": "High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-24 10:02:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-including-180243710.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TEVA",
    "timestamp": "2025-01-20 18:12:28",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 21.92,
    "priceChange": 1.11,
    "openPrice": 21.49,
    "prevClose": 21.68,
    "dayHigh": 21.99,
    "dayLow": 21.21,
    "volume": 8962900,
    "prevVolume": 7200000,
    "averageVolume": 8154088.888888889,
    "volumeChange": 24.48,
    "volumeVsAvg": 9.92,
    "recentVolumes": [
      15176800,
      7965000,
      11927100,
      7200000,
      8962900
    ],
    "marketCap": 24836456448,
    "fiftyTwoWeekHigh": 22.8,
    "fiftyTwoWeekLow": 11.48,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",
        "publisher": "TipRanks",
        "timestamp": "2025-01-18 05:20:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ozempic-xtandi-among-next-15-132048211.html"
      },
      {
        "title": "Update: Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-17 10:57:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/novo-nordisk-apos-ozempic-wegovy-185750170.html"
      },
      {
        "title": "Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations",
        "publisher": "Yahoo Finance",
        "timestamp": "2025-01-17 06:46:24",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/novo-nordisks-stock-down-4-as-the-feds-get-ready-for-a-second-round-of-drug-price-negotiations-144624687.html"
      },
      {
        "title": "How Teva Pharmaceuticals is thinking about Trump's return: CEO",
        "publisher": "Yahoo Finance Video",
        "timestamp": "2025-01-13 08:55:05",
        "type": "VIDEO",
        "url": "https://finance.yahoo.com/video/teva-pharmaceuticals-thinking-trumps-return-165505263.html"
      },
      {
        "title": "Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook",
        "publisher": "Zacks",
        "timestamp": "2025-01-13 08:31:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/amicus-posts-preliminary-2024-results-163100240.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VMD",
    "timestamp": "2025-01-20 18:12:28",
    "sector": "Healthcare",
    "industry": "Medical Devices",
    "price": 8.14,
    "priceChange": -0.37,
    "openPrice": 8.2,
    "prevClose": 8.17,
    "dayHigh": 8.23,
    "dayLow": 8.02,
    "volume": 150600,
    "prevVolume": 241700,
    "averageVolume": 159792.22222222222,
    "volumeChange": -37.69,
    "volumeVsAvg": -5.75,
    "recentVolumes": [
      59600,
      235300,
      167900,
      241700,
      150600
    ],
    "marketCap": 317333280,
    "fiftyTwoWeekHigh": 10.44,
    "fiftyTwoWeekLow": 6.21,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "3 US Growth Stocks With Up To 20% Insider Ownership",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-01 03:09:16",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/3-us-growth-stocks-20-110916773.html"
      },
      {
        "title": "Undiscovered Gems In The US Featuring 3 Promising Small Caps",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-20 06:07:30",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/undiscovered-gems-us-featuring-3-140730389.html"
      },
      {
        "title": "3 US Growth Stocks With High Insider Ownership And Up To 74% Earnings Growth",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-03 03:06:31",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/3-us-growth-stocks-high-110631169.html"
      },
      {
        "title": "Undiscovered Gems In The US Featuring Three Promising Small Caps",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-21 02:02:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/undiscovered-gems-us-featuring-three-100259956.html"
      },
      {
        "title": "Viemed Healthcare Announces Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 13:45:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/viemed-healthcare-announces-third-quarter-214500322.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VERU",
    "timestamp": "2025-01-20 18:12:29",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.98,
    "priceChange": 16.31,
    "openPrice": 0.84,
    "prevClose": 0.84,
    "dayHigh": 0.99,
    "dayLow": 0.83,
    "volume": 4912000,
    "prevVolume": 2760100,
    "averageVolume": 1132364.4444444445,
    "volumeChange": 77.96,
    "volumeVsAvg": 333.78,
    "recentVolumes": [
      1617000,
      1534300,
      1093600,
      2760100,
      4912000
    ],
    "marketCap": 142782944,
    "fiftyTwoWeekHigh": 1.92,
    "fiftyTwoWeekLow": 0.36,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "3 US Penny Stocks With Market Caps Under $200M To Consider",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-14 09:07:24",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/3-us-penny-stocks-market-170724528.html"
      },
      {
        "title": "Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline",
        "publisher": "Benzinga",
        "timestamp": "2024-12-31 08:29:59",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-sells-fc2-condom-business-162959484.html"
      },
      {
        "title": "Veru Sells Female Condom Business to Riva Ridge Capital for $18 Million",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-31 06:12:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-sells-female-condom-business-141207346.html"
      },
      {
        "title": "Veru Announces the Sale of the FC2 Female Condom\u00ae (Internal Condom) Business",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-31 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-announces-sale-fc2-female-133000826.html"
      },
      {
        "title": "Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates",
        "publisher": "Zacks",
        "timestamp": "2024-12-16 16:00:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/veru-inc-veru-reports-q4-000002701.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VRCA",
    "timestamp": "2025-01-20 18:12:29",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.67,
    "priceChange": 4.69,
    "openPrice": 0.64,
    "prevClose": 0.64,
    "dayHigh": 0.67,
    "dayLow": 0.63,
    "volume": 181800,
    "prevVolume": 251700,
    "averageVolume": 795456.6666666666,
    "volumeChange": -27.77,
    "volumeVsAvg": -77.15,
    "recentVolumes": [
      293000,
      217000,
      300100,
      251700,
      181800
    ],
    "marketCap": 61339536,
    "fiftyTwoWeekHigh": 11.41,
    "fiftyTwoWeekLow": 0.61,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Verrica Provides Business and Operational Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-20 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-provides-business-operational-120000978.html"
      },
      {
        "title": "Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-09 13:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-reports-inducement-grant-under-211500226.html"
      },
      {
        "title": "Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-06 05:57:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-apos-partner-torii-135750424.html"
      },
      {
        "title": "Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-06 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-pharmaceuticals-announces-development-partner-130000537.html"
      },
      {
        "title": "Verrica Announces Pricing of $42.0 Million Public Offering",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-21 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/verrica-announces-pricing-42-0-123000357.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SIGA",
    "timestamp": "2025-01-20 18:12:30",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 6.23,
    "priceChange": -0.16,
    "openPrice": 6.29,
    "prevClose": 6.24,
    "dayHigh": 6.39,
    "dayLow": 6.19,
    "volume": 278500,
    "prevVolume": 284400,
    "averageVolume": 519013.3333333333,
    "volumeChange": -2.07,
    "volumeVsAvg": -46.34,
    "recentVolumes": [
      322900,
      396700,
      250300,
      284400,
      278500
    ],
    "marketCap": 444494272,
    "fiftyTwoWeekHigh": 12.83,
    "fiftyTwoWeekLow": 4.26,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts",
        "publisher": "Zacks",
        "timestamp": "2025-01-17 14:45:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/siga-technologies-inc-siga-stock-224522332.html"
      },
      {
        "title": "Siga Technologies Inc. (SIGA) Advances But Underperforms Market: Key Facts",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 14:50:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/siga-technologies-inc-siga-advances-225022506.html"
      },
      {
        "title": "SIGA\u2019s antiviral approved in Japan for orthopoxvirus treatment",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2025-01-03 03:40:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/d5d1225a-8813-3136-b3fb-611bb83cd18d/siga%E2%80%99s-antiviral-approved-in.html"
      },
      {
        "title": "Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox",
        "publisher": "Benzinga",
        "timestamp": "2025-01-02 07:10:22",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/japan-approves-siga-technologies-antiviral-151022382.html"
      },
      {
        "title": "SIGA Technologies Says Japan's Pharmaceutical Regulator Approves its Antiviral Treatment for Smallpox, MPox, Cowpox",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-02 05:15:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/siga-technologies-says-japan-apos-131508053.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "INMD",
    "timestamp": "2025-01-20 18:12:31",
    "sector": "Healthcare",
    "industry": "Medical Devices",
    "price": 16.79,
    "priceChange": 1.33,
    "openPrice": 16.65,
    "prevClose": 16.57,
    "dayHigh": 16.8,
    "dayLow": 16.42,
    "volume": 1005900,
    "prevVolume": 962500,
    "averageVolume": 1081767.7777777778,
    "volumeChange": 4.51,
    "volumeVsAvg": -7.01,
    "recentVolumes": [
      814300,
      714600,
      731400,
      962500,
      1005900
    ],
    "marketCap": 1280222464,
    "fiftyTwoWeekHigh": 26.8,
    "fiftyTwoWeekLow": 14.87,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "InMode (NASDAQ:INMD) earnings and shareholder returns have been trending downwards for the last three years, but the stock rallies 5.1% this past week",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-20 03:35:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmode-nasdaq-inmd-earnings-shareholder-113548290.html"
      },
      {
        "title": "InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-16 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmode-report-fourth-quarter-full-120000627.html"
      },
      {
        "title": "InMode Pressed by Investor Doma Perpetual to Launch Tender Offer, Buy Back Stock",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-15 07:17:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/inmode-pressed-investor-doma-perpetual-151743439.html"
      },
      {
        "title": "DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-15 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/doma-perpetual-sends-letter-urging-130500717.html"
      },
      {
        "title": "Barclays Adjusts Price Target on InMode to $26 From $27, Maintains Overweight Rating",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-09 03:05:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/barclays-adjusts-price-target-inmode-110521725.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "EXEL",
    "timestamp": "2025-01-20 18:12:31",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 36.18,
    "priceChange": -1.01,
    "openPrice": 36.76,
    "prevClose": 36.55,
    "dayHigh": 36.92,
    "dayLow": 35.99,
    "volume": 2864800,
    "prevVolume": 2115400,
    "averageVolume": 2185333.3333333335,
    "volumeChange": 35.43,
    "volumeVsAvg": 31.09,
    "recentVolumes": [
      2602500,
      4257400,
      4931000,
      2115400,
      2864800
    ],
    "marketCap": 10337959936,
    "fiftyTwoWeekHigh": 37.59,
    "fiftyTwoWeekLow": 20.02,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio",
        "publisher": "Zacks",
        "timestamp": "2025-01-20 06:50:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-1-momentum-stock-could-145013422.html"
      },
      {
        "title": "Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-20 03:57:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adding-exelixis-nasdaq-exel-watchlist-115710564.html"
      },
      {
        "title": "William O'Neil Initiates Exelixis at Buy",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-17 04:40:16",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/william-o-apos-neil-initiates-124016532.html"
      },
      {
        "title": "Oppenheimer Adjusts Price Target on Exelixis to $41 From $38, Maintains Outperform Rating",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-16 06:01:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/oppenheimer-adjusts-price-target-exelixis-140107519.html"
      },
      {
        "title": "BeiGene Stock Meets 80-Plus RS Rating Benchmark",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-15 12:44:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/9b29f90d-c811-39b2-90cb-1e1db0c183f1/beigene-stock-meets-80-plus.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CPRX",
    "timestamp": "2025-01-20 18:12:32",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 22.76,
    "priceChange": 0.44,
    "openPrice": 22.81,
    "prevClose": 22.66,
    "dayHigh": 23.01,
    "dayLow": 22.46,
    "volume": 4930100,
    "prevVolume": 1592000,
    "averageVolume": 1053724.4444444445,
    "volumeChange": 209.68,
    "volumeVsAvg": 367.87,
    "recentVolumes": [
      1614300,
      1359900,
      1496100,
      1592000,
      4930100
    ],
    "marketCap": 2717039104,
    "fiftyTwoWeekHigh": 24.27,
    "fiftyTwoWeekLow": 13.12,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "BeiGene Stock Meets 80-Plus RS Rating Benchmark",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-15 12:44:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/9b29f90d-c811-39b2-90cb-1e1db0c183f1/beigene-stock-meets-80-plus.html"
      },
      {
        "title": "BridgeBio Pharma Stock Earns 87 RS Rating",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-14 12:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/15b1bee2-049c-37e2-b6ae-d16f3b1648a8/bridgebio-pharma-stock-earns.html"
      },
      {
        "title": "Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?",
        "publisher": "Zacks",
        "timestamp": "2025-01-09 05:17:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/catalyst-cprx-soars-16-7-131700002.html"
      },
      {
        "title": "IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-08 13:10:04",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/0c47eecf-6c38-381e-a1d0-b6c85ac37dc2/ibd-tech-leader-catalyst.html"
      },
      {
        "title": "Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE\u00ae (amifampridine) Patent Litigation with Teva Pharmaceuticals",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-08 09:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/catalyst-pharmaceuticals-announces-settlement-firdapse-173000231.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "HALO",
    "timestamp": "2025-01-20 18:12:33",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 54.8,
    "priceChange": -1.03,
    "openPrice": 55.66,
    "prevClose": 55.37,
    "dayHigh": 55.72,
    "dayLow": 54.76,
    "volume": 942000,
    "prevVolume": 1570000,
    "averageVolume": 1607598.888888889,
    "volumeChange": -40.0,
    "volumeVsAvg": -41.4,
    "recentVolumes": [
      2016100,
      1360900,
      1959500,
      1570000,
      942000
    ],
    "marketCap": 6972039680,
    "fiftyTwoWeekHigh": 65.53,
    "fiftyTwoWeekLow": 33.15,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "BeiGene Stock Meets 80-Plus RS Rating Benchmark",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-15 12:44:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/9b29f90d-c811-39b2-90cb-1e1db0c183f1/beigene-stock-meets-80-plus.html"
      },
      {
        "title": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 06:40:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/value-investor-1-stock-could-144012967.html"
      },
      {
        "title": "Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 00:48:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-incyte-084800976.html"
      },
      {
        "title": "BridgeBio Pharma Stock Earns 87 RS Rating",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-14 12:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/15b1bee2-049c-37e2-b6ae-d16f3b1648a8/bridgebio-pharma-stock-earns.html"
      },
      {
        "title": "5 Biotech Stocks Worth Adding to Your Portfolio in 2025",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 07:02:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/5-biotech-stocks-worth-adding-150200564.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NVOS",
    "timestamp": "2025-01-20 18:12:33",
    "sector": "Healthcare",
    "industry": "Medical Care Facilities",
    "price": 0.08,
    "priceChange": 11.27,
    "openPrice": 0.07,
    "prevClose": 0.07,
    "dayHigh": 0.08,
    "dayLow": 0.06,
    "volume": 87300,
    "prevVolume": 41600,
    "averageVolume": 462783.3333333333,
    "volumeChange": 109.86,
    "volumeVsAvg": -81.14,
    "recentVolumes": [
      143900,
      41100,
      317600,
      41600,
      87300
    ],
    "marketCap": 1558685,
    "fiftyTwoWeekHigh": 1.41,
    "fiftyTwoWeekLow": 0.03,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results",
        "publisher": "Business Wire",
        "timestamp": "2024-12-18 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/novo-integrated-sciences-reports-2024-210500508.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ATAI",
    "timestamp": "2025-01-20 18:12:34",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.46,
    "priceChange": 5.04,
    "openPrice": 1.39,
    "prevClose": 1.39,
    "dayHigh": 1.49,
    "dayLow": 1.39,
    "volume": 958200,
    "prevVolume": 711700,
    "averageVolume": 1349980.0,
    "volumeChange": 34.64,
    "volumeVsAvg": -29.02,
    "recentVolumes": [
      1276100,
      1297500,
      1460800,
      711700,
      958200
    ],
    "marketCap": 244990928,
    "fiftyTwoWeekHigh": 2.85,
    "fiftyTwoWeekLow": 1.03,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Weekly Roundup on the Cannabis Sector & Psychedelic Sector",
        "publisher": "Market Exclusive",
        "timestamp": "2025-01-12 16:58:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-005855076.html"
      },
      {
        "title": "atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-10 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/atai-life-sciences-announces-key-120000863.html"
      },
      {
        "title": "US Penny Stocks To Consider In December 2024",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-30 05:12:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/us-penny-stocks-consider-december-131248717.html"
      },
      {
        "title": "Oxbridge Re Holdings Among 3 US Penny Stocks To Watch",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-19 05:04:46",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/oxbridge-holdings-among-3-us-130446188.html"
      },
      {
        "title": "atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/atai-life-sciences-reports-third-130000969.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BNGO",
    "timestamp": "2025-01-20 18:12:34",
    "sector": "Healthcare",
    "industry": "Medical Instruments & Supplies",
    "price": 0.19,
    "priceChange": -10.0,
    "openPrice": 0.21,
    "prevClose": 0.21,
    "dayHigh": 0.21,
    "dayLow": 0.19,
    "volume": 7246700,
    "prevVolume": 15390600,
    "averageVolume": 5711220.0,
    "volumeChange": -52.91,
    "volumeVsAvg": 26.89,
    "recentVolumes": [
      10266200,
      8936900,
      11831900,
      15390600,
      7246700
    ],
    "marketCap": 27041960,
    "fiftyTwoWeekHigh": 1.4,
    "fiftyTwoWeekLow": 0.18,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-14 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-announces-ogm-preimplantation-genetic-130000375.html"
      },
      {
        "title": "Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-reports-preliminary-fourth-quarter-130000031.html"
      },
      {
        "title": "Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-07 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-announces-publication-showing-ogm-130000116.html"
      },
      {
        "title": "BioNano Genomics Announces $10 Million Direct Offering",
        "publisher": "TipRanks",
        "timestamp": "2025-01-07 04:30:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-genomics-announces-10-million-123014251.html"
      },
      {
        "title": "Bionano Genomics Closes $10 Million Offering of Shares, Warrants",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-06 14:12:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/bionano-genomics-closes-10-million-221255150.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ENOV",
    "timestamp": "2025-01-20 18:12:35",
    "sector": "Industrials",
    "industry": "Specialty Industrial Machinery",
    "price": 46.61,
    "priceChange": 2.51,
    "openPrice": 45.83,
    "prevClose": 45.47,
    "dayHigh": 46.95,
    "dayLow": 45.81,
    "volume": 541600,
    "prevVolume": 490700,
    "averageVolume": 791755.5555555555,
    "volumeChange": 10.37,
    "volumeVsAvg": -31.6,
    "recentVolumes": [
      10728800,
      1403800,
      731100,
      490700,
      541600
    ],
    "marketCap": 2605474560,
    "fiftyTwoWeekHigh": 65.03,
    "fiftyTwoWeekLow": 38.27,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Enovis\u2122 Announces Leadership Change to International Surgical Business",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-17 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/enovis-announces-leadership-change-international-110000986.html"
      },
      {
        "title": "Centene Expands Care in Hawaii With a Residential Program",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 09:38:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/centene-expands-care-hawaii-residential-173800099.html"
      },
      {
        "title": "Instacart Is Joining the S&P MidCap 400. Its Stock Is Rising.",
        "publisher": "Investopedia",
        "timestamp": "2025-01-08 07:36:04",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/77260674-8dc1-32bf-9785-de4c71931746/instacart-is-joining-the-s%26p.html"
      },
      {
        "title": "Maplebear to Replace Enovis in S&P MidCap 400 Index",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-08 00:34:18",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/maplebear-replace-enovis-p-midcap-083418894.html"
      },
      {
        "title": "Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-07 15:19:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/maplebear-set-join-p-midcap-231900883.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "BIIB",
    "timestamp": "2025-01-20 18:12:36",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 140.58,
    "priceChange": -0.46,
    "openPrice": 142.66,
    "prevClose": 141.23,
    "dayHigh": 143.5,
    "dayLow": 140.06,
    "volume": 1149900,
    "prevVolume": 1198700,
    "averageVolume": 1430397.7777777778,
    "volumeChange": -4.07,
    "volumeVsAvg": -19.61,
    "recentVolumes": [
      1142800,
      1710000,
      1557600,
      1198700,
      1149900
    ],
    "marketCap": 20480806912,
    "fiftyTwoWeekHigh": 251.99,
    "fiftyTwoWeekLow": 140.05,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 09:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biotech-stock-roundup-mrna-ntla-170000544.html"
      },
      {
        "title": "Eli Lilly Stock Has Tumbled 22% Since Its August High. Is It A Buy Or A Sell?",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-16 07:06:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/75ad41f4-79f0-3b48-af19-38b6a6e1e059/eli-lilly-stock-has-tumbled.html"
      },
      {
        "title": "At JPM, Biogen CEO tries to take down the deal temperature",
        "publisher": "BioPharma Dive",
        "timestamp": "2025-01-15 03:52:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/6196f5f9-a552-355c-99cb-d5a02a0245bc/at-jpm%2C-biogen-ceo-tries-to.html"
      },
      {
        "title": "Federal watchdog cites concerns with FDA\u2019s accelerated approval process",
        "publisher": "BioPharma Dive",
        "timestamp": "2025-01-15 03:26:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/78101831-c14d-3306-bae9-439f7bbed989/federal-watchdog-cites.html"
      },
      {
        "title": "Biogen CEO sees no burning need for more acquisitions",
        "publisher": "Reuters",
        "timestamp": "2025-01-14 15:00:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biogen-ceo-sees-no-burning-230041149.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MIST",
    "timestamp": "2025-01-20 18:12:36",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.97,
    "priceChange": 0.51,
    "openPrice": 1.99,
    "prevClose": 1.96,
    "dayHigh": 2.02,
    "dayLow": 1.94,
    "volume": 211400,
    "prevVolume": 312900,
    "averageVolume": 379931.1111111111,
    "volumeChange": -32.44,
    "volumeVsAvg": -44.36,
    "recentVolumes": [
      574500,
      467900,
      312700,
      312900,
      211400
    ],
    "marketCap": 105589240,
    "fiftyTwoWeekHigh": 2.75,
    "fiftyTwoWeekLow": 1.12,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-07 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-reports-inducement-grants-130000943.html"
      },
      {
        "title": "Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-25 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-present-piper-sandler-130000760.html"
      },
      {
        "title": "After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright",
        "publisher": "Zacks",
        "timestamp": "2024-11-19 06:55:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/golden-cross-milestone-pharmaceuticals-mist-145502861.html"
      },
      {
        "title": "Milestone Pharmaceuticals: Q3 Earnings Snapshot",
        "publisher": "Associated Press Finance",
        "timestamp": "2024-11-12 06:17:33",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-q3-earnings-snapshot-141733662.html"
      },
      {
        "title": "Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-12 06:03:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/milestone-pharmaceuticals-reports-third-quarter-140300144.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ARDX",
    "timestamp": "2025-01-20 18:12:37",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 5.01,
    "priceChange": -3.0,
    "openPrice": 5.2,
    "prevClose": 5.16,
    "dayHigh": 5.29,
    "dayLow": 5.0,
    "volume": 5825000,
    "prevVolume": 5675800,
    "averageVolume": 4240008.888888889,
    "volumeChange": 2.63,
    "volumeVsAvg": 37.38,
    "recentVolumes": [
      10119500,
      8044000,
      5031500,
      5675800,
      5825000
    ],
    "marketCap": 1186638592,
    "fiftyTwoWeekHigh": 10.13,
    "fiftyTwoWeekLow": 4.32,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 06:07:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ardelyx-ardx-moves-16-0-140700020.html"
      },
      {
        "title": "Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 05:03:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ardelyx-provides-increasing-commercial-momentum-130300199.html"
      },
      {
        "title": "Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-06 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ardelyx-present-43rd-annual-j-130000703.html"
      },
      {
        "title": "Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now?",
        "publisher": "Insider Monkey",
        "timestamp": "2024-12-30 11:41:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-ardelyx-ardx-one-best-194143123.html"
      },
      {
        "title": "Exploring 3 High Growth Tech Stocks in the United States",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-30 06:08:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-140839244.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CVM",
    "timestamp": "2025-01-20 18:12:37",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.4,
    "priceChange": 0.12,
    "openPrice": 0.41,
    "prevClose": 0.4,
    "dayHigh": 0.41,
    "dayLow": 0.39,
    "volume": 249900,
    "prevVolume": 275400,
    "averageVolume": 771487.7777777778,
    "volumeChange": -9.26,
    "volumeVsAvg": -67.61,
    "recentVolumes": [
      820700,
      275600,
      557900,
      275400,
      249900
    ],
    "marketCap": 29835478,
    "fiftyTwoWeekHigh": 3.08,
    "fiftyTwoWeekLow": 0.36,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer",
        "publisher": "Business Wire",
        "timestamp": "2025-01-14 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-reports-fiscal-2024-140000964.html"
      },
      {
        "title": "CEL-SCI Completes $5 Million 'Best Efforts' Stock Sale",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-31 13:25:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-completes-5-million-212500089.html"
      },
      {
        "title": "CEL-SCI Announces Closing of $5 Million Offering",
        "publisher": "Business Wire",
        "timestamp": "2024-12-31 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-announces-closing-5-210500250.html"
      },
      {
        "title": "CEL-SCI Prices $5 Million Stock Offering",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-30 00:41:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-prices-5-million-084107002.html"
      },
      {
        "title": "CEL-SCI Announces Pricing of $5 Million Public Offering",
        "publisher": "Business Wire",
        "timestamp": "2024-12-29 17:41:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cel-sci-announces-pricing-5-014100383.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ACLS",
    "timestamp": "2025-01-20 18:12:38",
    "sector": "Technology",
    "industry": "Semiconductor Equipment & Materials",
    "price": 71.59,
    "priceChange": -0.54,
    "openPrice": 73.78,
    "prevClose": 71.98,
    "dayHigh": 73.96,
    "dayLow": 71.35,
    "volume": 324800,
    "prevVolume": 415200,
    "averageVolume": 627073.3333333334,
    "volumeChange": -21.77,
    "volumeVsAvg": -48.2,
    "recentVolumes": [
      510200,
      333200,
      390500,
      415200,
      324800
    ],
    "marketCap": 2327761920,
    "fiftyTwoWeekHigh": 158.61,
    "fiftyTwoWeekLow": 66.75,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Are Options Traders Betting on a Big Move in Axcelis Technologies (ACLS) Stock?",
        "publisher": "Zacks",
        "timestamp": "2025-01-10 05:44:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/options-traders-betting-big-move-134400967.html"
      },
      {
        "title": "Calculating The Intrinsic Value Of Axcelis Technologies, Inc. (NASDAQ:ACLS)",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-09 04:31:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/calculating-intrinsic-value-axcelis-technologies-123112747.html"
      },
      {
        "title": "Axcelis Technologies Inc (NASDAQ:ACLS): Vulnerable to Disruption and Market Downturns",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-08 07:42:19",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axcelis-technologies-inc-nasdaq-acls-154219557.html"
      },
      {
        "title": "Axcelis to Participate in the 27th Annual Needham Growth Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-06 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/axcelis-participate-27th-annual-needham-130000949.html"
      },
      {
        "title": "Here's Why Axcelis Technologies (ACLS) Gained But Lagged the Market Today",
        "publisher": "Zacks",
        "timestamp": "2024-12-20 15:15:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-why-axcelis-technologies-acls-231508488.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "IDYA",
    "timestamp": "2025-01-20 18:12:39",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 22.16,
    "priceChange": -2.46,
    "openPrice": 22.94,
    "prevClose": 22.72,
    "dayHigh": 23.0,
    "dayLow": 22.1,
    "volume": 528200,
    "prevVolume": 565400,
    "averageVolume": 882340.0,
    "volumeChange": -6.58,
    "volumeVsAvg": -40.14,
    "recentVolumes": [
      652300,
      1142400,
      565900,
      565400,
      528200
    ],
    "marketCap": 1917057408,
    "fiftyTwoWeekHigh": 47.73,
    "fiftyTwoWeekLow": 22.1,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-12 09:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-biosciences-announces-participation-43rd-170000732.html"
      },
      {
        "title": "IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-30 01:34:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-biosciences-enters-licensing-agreement-093443617.html"
      },
      {
        "title": "IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-29 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-biosciences-enters-exclusive-license-110000070.html"
      },
      {
        "title": "IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-27 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-biosciences-announces-inducement-grants-110000733.html"
      },
      {
        "title": "IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-17 04:30:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ideaya-biosciences-gets-move-forward-123055974.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "RYTM",
    "timestamp": "2025-01-20 18:12:39",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 54.54,
    "priceChange": -0.22,
    "openPrice": 55.2,
    "prevClose": 54.66,
    "dayHigh": 56.45,
    "dayLow": 54.39,
    "volume": 593100,
    "prevVolume": 514100,
    "averageVolume": 527557.7777777778,
    "volumeChange": 15.37,
    "volumeVsAvg": 12.42,
    "recentVolumes": [
      495800,
      534400,
      618900,
      514100,
      593100
    ],
    "marketCap": 3351870208,
    "fiftyTwoWeekHigh": 68.58,
    "fiftyTwoWeekLow": 35.17,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-10 04:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-preliminary-fourth-121500219.html"
      },
      {
        "title": "Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential",
        "publisher": "TipRanks",
        "timestamp": "2025-01-02 07:15:07",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jefferies-starts-rhythm-pharmaceuticals-buy-151507419.html"
      },
      {
        "title": "Jefferies Initiates Rhythm Pharmaceuticals at Buy With $80 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-02 05:01:29",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jefferies-initiates-rhythm-pharmaceuticals-buy-130129935.html"
      },
      {
        "title": "Exploring 3 High Growth Tech Stocks In The United States",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-23 06:06:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-140650910.html"
      },
      {
        "title": "Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-23 05:27:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rhythm-pharmaceuticals-nasdaq-rytm-investors-132754425.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TWST",
    "timestamp": "2025-01-20 18:12:40",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 47.56,
    "priceChange": 3.68,
    "openPrice": 46.72,
    "prevClose": 45.87,
    "dayHigh": 48.8,
    "dayLow": 46.11,
    "volume": 617000,
    "prevVolume": 670700,
    "averageVolume": 754196.6666666666,
    "volumeChange": -8.01,
    "volumeVsAvg": -18.19,
    "recentVolumes": [
      489400,
      916100,
      741300,
      670700,
      617000
    ],
    "marketCap": 2833662976,
    "fiftyTwoWeekHigh": 60.9,
    "fiftyTwoWeekLow": 27.41,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Companies Like Twist Bioscience (NASDAQ:TWST) Can Afford To Invest In Growth",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-31 03:14:16",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/companies-twist-bioscience-nasdaq-twst-111416479.html"
      },
      {
        "title": "All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy",
        "publisher": "Zacks",
        "timestamp": "2024-12-27 09:00:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/know-twist-bioscience-twst-rating-170010642.html"
      },
      {
        "title": "Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?",
        "publisher": "Zacks",
        "timestamp": "2024-12-23 05:48:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-twst-surges-9-134800525.html"
      },
      {
        "title": "Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-12-19 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-present-43rd-annual-130000579.html"
      },
      {
        "title": "Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now",
        "publisher": "Zacks",
        "timestamp": "2024-12-16 06:55:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/twist-bioscience-twst-could-support-145508466.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "STEM",
    "timestamp": "2025-01-20 18:12:41",
    "sector": "Utilities",
    "industry": "Utilities - Renewable",
    "price": 0.7,
    "priceChange": 0.29,
    "openPrice": 0.71,
    "prevClose": 0.7,
    "dayHigh": 0.75,
    "dayLow": 0.65,
    "volume": 10574800,
    "prevVolume": 13860400,
    "averageVolume": 10409006.666666666,
    "volumeChange": -23.7,
    "volumeVsAvg": 1.59,
    "recentVolumes": [
      20848100,
      50891400,
      15431600,
      13860400,
      10574800
    ],
    "marketCap": 114041728,
    "fiftyTwoWeekHigh": 3.58,
    "fiftyTwoWeekLow": 0.3,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Stem Names Software Veteran Arun Narayanan as Chief Executive Officer",
        "publisher": "Business Wire",
        "timestamp": "2025-01-16 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-names-software-veteran-arun-133000741.html"
      },
      {
        "title": "Stem to Support 484 MW Hungarian Solar Portfolio in Company\u2019s Largest Software Deal in EMEA",
        "publisher": "Business Wire",
        "timestamp": "2025-01-14 02:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-support-484-mw-hungarian-100000726.html"
      },
      {
        "title": "Looking for a Fast-paced Momentum Stock at a Bargain? Consider Stem (STEM)",
        "publisher": "Zacks",
        "timestamp": "2025-01-13 05:50:23",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/looking-fast-paced-momentum-stock-135023045.html"
      },
      {
        "title": "Stem (STEM) Upgraded to Buy: What Does It Mean for the Stock?",
        "publisher": "Zacks",
        "timestamp": "2024-12-31 09:00:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/stem-stem-upgraded-buy-does-170011407.html"
      },
      {
        "title": "Charged: Analyst sees Tesla Q4 deliveries just above expectations",
        "publisher": "TipRanks",
        "timestamp": "2024-12-24 07:05:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/charged-analyst-sees-tesla-q4-150520383.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GERN",
    "timestamp": "2025-01-20 18:12:42",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.89,
    "priceChange": -0.86,
    "openPrice": 2.94,
    "prevClose": 2.92,
    "dayHigh": 2.98,
    "dayLow": 2.85,
    "volume": 8638000,
    "prevVolume": 6008300,
    "averageVolume": 9639706.666666666,
    "volumeChange": 43.77,
    "volumeVsAvg": -10.39,
    "recentVolumes": [
      23394900,
      12409800,
      6594800,
      6008300,
      8638000
    ],
    "marketCap": 1747007872,
    "fiftyTwoWeekHigh": 5.34,
    "fiftyTwoWeekLow": 1.64,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Geron Stock Rallies More Than 60% in a Year: Here's Why",
        "publisher": "Zacks",
        "timestamp": "2025-01-08 07:33:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/geron-stock-rallies-more-60-153300239.html"
      },
      {
        "title": "Here\u2019s Why Geron Corp. (NASDAQ:GERN) Crashed Today",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-06 18:20:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-geron-corp-nasdaq-gern-022014378.html"
      },
      {
        "title": "Why Is Geron Corporation (GERN) the Best Long-Term Penny Stock to Buy According to Hedge Funds?",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-06 12:30:46",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-geron-corporation-gern-best-203046301.html"
      },
      {
        "title": "Why GERN Stock (GERN) is Skyrocketing",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-02 00:50:29",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-gern-stock-gern-skyrocketing-085029623.html"
      },
      {
        "title": "Is Geron Corporation (GERN) the Best Penny Stock to Buy for 2025?",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-01 03:58:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/geron-corporation-gern-best-penny-115856453.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "VIR",
    "timestamp": "2025-01-20 18:12:42",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 10.11,
    "priceChange": 0.6,
    "openPrice": 10.16,
    "prevClose": 10.05,
    "dayHigh": 10.28,
    "dayLow": 10.02,
    "volume": 1086700,
    "prevVolume": 1346100,
    "averageVolume": 1718361.111111111,
    "volumeChange": -19.27,
    "volumeVsAvg": -36.76,
    "recentVolumes": [
      4556800,
      1962200,
      2222100,
      1346100,
      1086700
    ],
    "marketCap": 1392349184,
    "fiftyTwoWeekHigh": 14.45,
    "fiftyTwoWeekLow": 6.56,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why",
        "publisher": "Benzinga",
        "timestamp": "2025-01-10 11:32:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/morgan-stanley-doubles-vir-biotechnology-193221160.html"
      },
      {
        "title": "VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates",
        "publisher": "Zacks",
        "timestamp": "2025-01-09 08:42:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vir-stock-early-safety-efficacy-164200842.html"
      },
      {
        "title": "Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20",
        "publisher": "Investing.com",
        "timestamp": "2025-01-09 05:30:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/morgan-stanley-upgrades-vir-biotechnology-133045186.html"
      },
      {
        "title": "Vir Biotechnology Reports Promising Trial Results for Cancer Therapies",
        "publisher": "TipRanks",
        "timestamp": "2025-01-09 05:18:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/vir-biotechnology-reports-promising-trial-131810104.html"
      },
      {
        "title": "Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-08 13:06:15",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/1a0940ce-f170-3e50-9152-99b0891533f5/vir-biotechnology-catapults.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ALKS",
    "timestamp": "2025-01-20 18:12:43",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 29.49,
    "priceChange": -0.87,
    "openPrice": 29.98,
    "prevClose": 29.75,
    "dayHigh": 30.04,
    "dayLow": 29.27,
    "volume": 1098400,
    "prevVolume": 2240200,
    "averageVolume": 1675471.111111111,
    "volumeChange": -50.97,
    "volumeVsAvg": -34.44,
    "recentVolumes": [
      1100700,
      1198800,
      1336500,
      2240200,
      1098400
    ],
    "marketCap": 4768334336,
    "fiftyTwoWeekHigh": 32.88,
    "fiftyTwoWeekLow": 22.9,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-17 10:35:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/646ae987-4a1c-35a8-8f94-7bfeaae7f4cf/the-cream-of-the-crop%3A-5.html"
      },
      {
        "title": "Onera\u2019s validation trial of home polysomnography sleep device succeeds",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2025-01-13 09:48:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/9e12809f-1a5f-33b5-97b5-626ab31e3bab/onera%E2%80%99s-validation-trial-of.html"
      },
      {
        "title": "Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-02 13:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/alkermes-present-43rd-annual-j-210000662.html"
      },
      {
        "title": "Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)?",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-31 04:44:57",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/declining-stock-solid-fundamentals-market-124457304.html"
      },
      {
        "title": "Alkermes Insider Sold Shares Worth $1,961,406, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-10 00:29:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/alkermes-insider-sold-shares-worth-082935811.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "AMPH",
    "timestamp": "2025-01-20 18:12:44",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 35.68,
    "priceChange": 0.06,
    "openPrice": 35.67,
    "prevClose": 35.66,
    "dayHigh": 35.96,
    "dayLow": 35.27,
    "volume": 410500,
    "prevVolume": 1060400,
    "averageVolume": 462036.6666666667,
    "volumeChange": -61.29,
    "volumeVsAvg": -11.15,
    "recentVolumes": [
      461900,
      605700,
      908100,
      1060400,
      410500
    ],
    "marketCap": 1716505984,
    "fiftyTwoWeekHigh": 56.77,
    "fiftyTwoWeekLow": 34.6,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "ACCESS Newswire",
        "timestamp": "2025-01-08 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/amphastar-pharmaceuticals-present-43rd-annual-110000226.html"
      },
      {
        "title": "Amphastar Pharmaceuticals Insider Sold Shares Worth $672,815, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-16 14:27:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/amphastar-pharmaceuticals-insider-sold-shares-222700791.html"
      },
      {
        "title": "Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-05 03:08:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adding-amphastar-pharmaceuticals-nasdaq-amph-110850563.html"
      },
      {
        "title": "Implied Volatility Surging for Amphastar Pharmceuticals (AMPH) Stock Options",
        "publisher": "Zacks",
        "timestamp": "2024-12-04 11:54:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/implied-volatility-surging-amphastar-pharmceuticals-195400443.html"
      },
      {
        "title": "Why Amphastar Pharmaceuticals (AMPH) Is One of the Most Profitable Pharmaceutical Stocks Right Now?",
        "publisher": "Insider Monkey",
        "timestamp": "2024-11-30 13:27:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-amphastar-pharmaceuticals-amph-one-212755302.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SVRA",
    "timestamp": "2025-01-20 18:12:44",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.93,
    "priceChange": 0.86,
    "openPrice": 2.94,
    "prevClose": 2.91,
    "dayHigh": 2.95,
    "dayLow": 2.74,
    "volume": 985600,
    "prevVolume": 920300,
    "averageVolume": 1334240.0,
    "volumeChange": 7.1,
    "volumeVsAvg": -26.13,
    "recentVolumes": [
      1198700,
      1656300,
      1483500,
      920300,
      985600
    ],
    "marketCap": 502843712,
    "fiftyTwoWeekHigh": 5.7,
    "fiftyTwoWeekLow": 2.6,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-29 06:54:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-inc-nasdaq-svra-largely-145421624.html"
      },
      {
        "title": "Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 05:33:24",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wells-fargo-initiates-coverage-savara-133324342.html"
      },
      {
        "title": "Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-18 14:07:04",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-starts-biologics-license-application-220704716.html"
      },
      {
        "title": "Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)",
        "publisher": "Business Wire",
        "timestamp": "2024-12-18 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-initiates-rolling-submission-biologics-210500382.html"
      },
      {
        "title": "Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-12-17 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/savara-announces-participation-43rd-annual-210500051.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GH",
    "timestamp": "2025-01-20 18:12:45",
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "price": 36.63,
    "priceChange": -1.82,
    "openPrice": 37.58,
    "prevClose": 37.31,
    "dayHigh": 37.93,
    "dayLow": 36.45,
    "volume": 1139300,
    "prevVolume": 1247900,
    "averageVolume": 1907754.4444444445,
    "volumeChange": -8.7,
    "volumeVsAvg": -40.28,
    "recentVolumes": [
      2954600,
      2466900,
      1546500,
      1247900,
      1139300
    ],
    "marketCap": 4529526272,
    "fiftyTwoWeekHigh": 39.29,
    "fiftyTwoWeekLow": 15.81,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Guardant Health, Inc. (GH) Partners with ConcertAI to Launch Advanced Real-World Data Solution for Enhanced Cancer Treatment and Clinical Trials",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-20 09:07:37",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/guardant-health-inc-gh-partners-170737548.html"
      },
      {
        "title": "Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'",
        "publisher": "Investor's Business Daily",
        "timestamp": "2025-01-16 13:05:13",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/3e095b46-f3fe-38cf-b64c-5c898e455f2a/exact-sciences-stock-drops.html"
      },
      {
        "title": "Guardant Health, ConcertAI Working Together on Cancer Treatments",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-16 07:14:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/guardant-health-concertai-working-together-151443956.html"
      },
      {
        "title": "Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development",
        "publisher": "Business Wire",
        "timestamp": "2025-01-16 05:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/guardant-health-concertai-collaborate-form-130500070.html"
      },
      {
        "title": "JP Morgan 2025: Guardant reports $737m in preliminary full-year revenue",
        "publisher": "Medical Device Network",
        "timestamp": "2025-01-14 04:59:41",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/6468f8d9-35ca-3411-8ac6-5bfc18dfd6f5/jp-morgan-2025%3A-guardant.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "NTLA",
    "timestamp": "2025-01-20 18:12:46",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 9.5,
    "priceChange": 0.85,
    "openPrice": 9.49,
    "prevClose": 9.42,
    "dayHigh": 9.69,
    "dayLow": 9.32,
    "volume": 3331000,
    "prevVolume": 3442200,
    "averageVolume": 2530967.777777778,
    "volumeChange": -3.23,
    "volumeVsAvg": 31.61,
    "recentVolumes": [
      4049200,
      3171300,
      3354400,
      3442200,
      3331000
    ],
    "marketCap": 967565504,
    "fiftyTwoWeekHigh": 34.87,
    "fiftyTwoWeekLow": 9.25,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Intellia Loses 21.6% in a Week: How Should You Play the Stock?",
        "publisher": "Zacks",
        "timestamp": "2025-01-17 10:34:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intellia-loses-21-6-week-183400659.html"
      },
      {
        "title": "The Zacks Analyst Blog Moderna, Regeneron, Intellia  Sage and GSK",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 23:12:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/zacks-analyst-blog-moderna-regeneron-071200631.html"
      },
      {
        "title": "Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 09:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/biotech-stock-roundup-mrna-ntla-170000544.html"
      },
      {
        "title": "Intellia slashes workforce by 27% to focus on late stage CRISPR candidates",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2025-01-13 00:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/b43c764a-5192-3eb8-9361-3ec7fb452c2f/intellia-slashes-workforce-by.html"
      },
      {
        "title": "Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital",
        "publisher": "TipRanks",
        "timestamp": "2025-01-11 07:20:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/intellia-therapeutics-price-target-lowered-152038872.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SRPT",
    "timestamp": "2025-01-20 18:12:49",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 118.06,
    "priceChange": 0.85,
    "openPrice": 117.75,
    "prevClose": 117.06,
    "dayHigh": 118.45,
    "dayLow": 115.85,
    "volume": 649100,
    "prevVolume": 829500,
    "averageVolume": 896676.6666666666,
    "volumeChange": -21.75,
    "volumeVsAvg": -27.61,
    "recentVolumes": [
      1518100,
      1297300,
      659200,
      829500,
      649100
    ],
    "marketCap": 11271312384,
    "fiftyTwoWeekHigh": 173.25,
    "fiftyTwoWeekLow": 102.16,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-20 04:52:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sarepta-therapeutics-inc-srpt-bull-125253482.html"
      },
      {
        "title": "Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue",
        "publisher": "Business Wire",
        "timestamp": "2025-01-13 09:25:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sarepta-therapeutics-reports-preliminary-fourth-172500904.html"
      },
      {
        "title": "RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-07 04:31:29",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-cuts-price-target-sarepta-123129166.html"
      },
      {
        "title": "Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2025-01-06 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sarepta-therapeutics-present-43rd-annual-133000963.html"
      },
      {
        "title": "SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?",
        "publisher": "Zacks",
        "timestamp": "2025-01-06 04:40:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/srpt-stock-rises-23-time-124000929.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "RARE",
    "timestamp": "2025-01-20 18:12:50",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 40.01,
    "priceChange": -2.06,
    "openPrice": 41.22,
    "prevClose": 40.85,
    "dayHigh": 41.5,
    "dayLow": 39.99,
    "volume": 794400,
    "prevVolume": 753300,
    "averageVolume": 787886.6666666666,
    "volumeChange": 5.46,
    "volumeVsAvg": 0.83,
    "recentVolumes": [
      2179800,
      989700,
      1097100,
      753300,
      794400
    ],
    "marketCap": 3693772288,
    "fiftyTwoWeekHigh": 60.37,
    "fiftyTwoWeekLow": 37.02,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-17 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyx-reports-inducement-grant-under-213000430.html"
      },
      {
        "title": "Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-17 08:14:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-ultragenyx-pharmaceutical-rare-biotech-161438189.html"
      },
      {
        "title": "Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside",
        "publisher": "Benzinga",
        "timestamp": "2025-01-15 11:05:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyxs-multiple-commercial-assets-candidates-190535917.html"
      },
      {
        "title": "Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-12 08:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ultragenyx-reports-preliminary-2024-revenue-160000338.html"
      },
      {
        "title": "RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use",
        "publisher": "Zacks",
        "timestamp": "2025-01-07 07:14:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rares-cholesterol-drug-evkeeza-gains-151400355.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TRVI",
    "timestamp": "2025-01-20 18:12:50",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.76,
    "priceChange": -0.66,
    "openPrice": 3.82,
    "prevClose": 3.78,
    "dayHigh": 3.82,
    "dayLow": 3.71,
    "volume": 258500,
    "prevVolume": 288600,
    "averageVolume": 1342053.3333333333,
    "volumeChange": -10.43,
    "volumeVsAvg": -80.74,
    "recentVolumes": [
      675900,
      413400,
      384000,
      288600,
      258500
    ],
    "marketCap": 336015008,
    "fiftyTwoWeekHigh": 4.68,
    "fiftyTwoWeekLow": 1.3,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "What Makes Trevi Therapeutics (TRVI) a New Buy Stock",
        "publisher": "Zacks",
        "timestamp": "2025-01-08 09:00:11",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/makes-trevi-therapeutics-trvi-buy-170011341.html"
      },
      {
        "title": "B. Riley Adjusts Trevi Therapeutics' Price Target to $11 From $6, Maintains Buy Rating",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-08 05:32:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/b-riley-adjusts-trevi-therapeutics-133203284.html"
      },
      {
        "title": "Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-08 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/trevi-therapeutics-announces-company-updates-123000511.html"
      },
      {
        "title": "Trevi Therapeutics Prices $50 Million Underwritten Offering",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-16 07:33:37",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/trevi-therapeutics-prices-50-million-153337540.html"
      },
      {
        "title": "Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-16 04:36:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/trevi-therapeutics-announces-pricing-50-123600661.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "PGEN",
    "timestamp": "2025-01-20 18:12:51",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.11,
    "priceChange": -0.45,
    "openPrice": 1.13,
    "prevClose": 1.11,
    "dayHigh": 1.15,
    "dayLow": 1.08,
    "volume": 1154100,
    "prevVolume": 1700000,
    "averageVolume": 1153792.2222222222,
    "volumeChange": -32.11,
    "volumeVsAvg": 0.03,
    "recentVolumes": [
      1391700,
      702200,
      1088500,
      1700000,
      1154100
    ],
    "marketCap": 325084576,
    "fiftyTwoWeekHigh": 1.93,
    "fiftyTwoWeekLow": 0.65,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/precigen-present-plans-realizing-commercial-120000013.html"
      },
      {
        "title": "Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-09 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/precigen-present-43rd-annual-j-133000860.html"
      },
      {
        "title": "Exploring 3 Prominent High Growth Tech Stocks In The United States",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-01 06:02:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-3-prominent-high-growth-140252952.html"
      },
      {
        "title": "Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-30 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/precigen-completes-submission-bla-request-120000584.html"
      },
      {
        "title": "Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock",
        "publisher": "PR Newswire",
        "timestamp": "2024-12-27 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/precigen-announces-79-0-million-140000554.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "EVH",
    "timestamp": "2025-01-20 18:12:52",
    "sector": "Healthcare",
    "industry": "Health Information Services",
    "price": 10.0,
    "priceChange": -1.57,
    "openPrice": 10.3,
    "prevClose": 10.16,
    "dayHigh": 10.47,
    "dayLow": 9.96,
    "volume": 2709300,
    "prevVolume": 3993700,
    "averageVolume": 2394290.0,
    "volumeChange": -32.16,
    "volumeVsAvg": 13.16,
    "recentVolumes": [
      1454600,
      3825500,
      6958900,
      3993700,
      2709300
    ],
    "marketCap": 1150259968,
    "fiftyTwoWeekHigh": 35.0,
    "fiftyTwoWeekLow": 9.88,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "UBS Adjusts Price Target on Evolent Health to $14 From $27, Keeps Buy Rating",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-16 06:37:10",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ubs-adjusts-price-target-evolent-143710176.html"
      },
      {
        "title": "RBC Cuts Price Target on Evolent Health to $17 From $20, Keeps Outperform Rating",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-14 04:38:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-cuts-price-target-evolent-123803609.html"
      },
      {
        "title": "Needham Initiates Evolent Health at Buy With $15 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 07:18:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/needham-initiates-evolent-health-buy-151848617.html"
      },
      {
        "title": "High Growth Tech Stocks In The United States To Watch",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-09 10:04:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-united-180454612.html"
      },
      {
        "title": "Evolent Health, Inc. (NYSE:EVH): Are Analysts Optimistic?",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-01 03:02:42",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/evolent-health-inc-nyse-evh-110242062.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ARQT",
    "timestamp": "2025-01-20 18:12:52",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 12.67,
    "priceChange": -7.85,
    "openPrice": 13.84,
    "prevClose": 13.75,
    "dayHigh": 13.95,
    "dayLow": 12.61,
    "volume": 2290900,
    "prevVolume": 1250100,
    "averageVolume": 2036152.2222222222,
    "volumeChange": 83.26,
    "volumeVsAvg": 12.51,
    "recentVolumes": [
      2323200,
      1835700,
      1772200,
      1250100,
      2290900
    ],
    "marketCap": 1484130688,
    "fiftyTwoWeekHigh": 16.2,
    "fiftyTwoWeekLow": 3.59,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade",
        "publisher": "Zacks",
        "timestamp": "2025-01-16 06:55:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wall-street-analysts-believe-arcutis-145514098.html"
      },
      {
        "title": "Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-13 01:07:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcutis-biotherapeutics-expects-fiscal-q4-090705535.html"
      },
      {
        "title": "Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-12 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcutis-announces-preliminary-unaudited-fourth-133000962.html"
      },
      {
        "title": "High Growth Tech Stocks In The United States To Watch",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-09 10:04:54",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-united-180454612.html"
      },
      {
        "title": "Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-06 13:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arcutis-biotherapeutics-reports-inducement-grants-210000989.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "QNRX",
    "timestamp": "2025-01-20 18:12:53",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.57,
    "priceChange": -3.19,
    "openPrice": 0.58,
    "prevClose": 0.59,
    "dayHigh": 0.6,
    "dayLow": 0.57,
    "volume": 117300,
    "prevVolume": 215600,
    "averageVolume": 2645508.888888889,
    "volumeChange": -45.59,
    "volumeVsAvg": -95.57,
    "recentVolumes": [
      232900,
      218200,
      207500,
      215600,
      117300
    ],
    "marketCap": 4676700,
    "fiftyTwoWeekHigh": 6.18,
    "fiftyTwoWeekLow": 0.42,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-14 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-announces-further-positive-133000221.html"
      },
      {
        "title": "PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-07 11:29:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/prism-marketview-spotlights-quoin-pharmaceuticals-192900898.html"
      },
      {
        "title": "Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-06 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-announces-additional-positive-133000466.html"
      },
      {
        "title": "Quoin Pharmaceuticals Insider Bought Shares Worth $250,000, According to a Recent SEC Filing",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-27 14:22:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-insider-bought-shares-222203829.html"
      },
      {
        "title": "Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 08:17:05",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/quoin-pharmaceuticals-prices-6-8-161705500.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SYRS",
    "timestamp": "2025-01-20 18:12:53",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.22,
    "priceChange": 5.9,
    "openPrice": 0.21,
    "prevClose": 0.2,
    "dayHigh": 0.23,
    "dayLow": 0.21,
    "volume": 1124500,
    "prevVolume": 2316600,
    "averageVolume": 6712023.333333333,
    "volumeChange": -51.46,
    "volumeVsAvg": -83.25,
    "recentVolumes": [
      1107900,
      1462200,
      1744700,
      2316600,
      1124500
    ],
    "marketCap": 5887050,
    "fiftyTwoWeekHigh": 7.96,
    "fiftyTwoWeekLow": 0.18,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Kia starts series production of Syros in India",
        "publisher": "Just Auto",
        "timestamp": "2025-01-20 04:23:34",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/8b0325df-e065-31d6-b083-9ec0e532473f/kia-starts-series-production.html"
      },
      {
        "title": "South Africa\u2019s Westfalia Fruit acquires Belgian avocado products maker Syros",
        "publisher": "Just Food",
        "timestamp": "2025-01-07 01:58:39",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/17395cf7-7e35-3542-bc47-52f906a7b857/south-africa%E2%80%99s-westfalia.html"
      },
      {
        "title": "Kia launches Syros compact SUV in India",
        "publisher": "Just Auto",
        "timestamp": "2024-12-20 03:59:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/eb92fdf5-772e-3bd6-bb48-affdcd40fb15/kia-launches-syros-compact.html"
      },
      {
        "title": "Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal",
        "publisher": "Zacks",
        "timestamp": "2024-11-14 07:24:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syros-stock-plunges-lead-cancer-152400773.html"
      },
      {
        "title": "Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright",
        "publisher": "TipRanks",
        "timestamp": "2024-11-14 03:35:45",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syros-pharmaceuticals-downgraded-neutral-buy-113545652.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MNKD",
    "timestamp": "2025-01-20 18:12:56",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 6.01,
    "priceChange": 0.0,
    "openPrice": 6.04,
    "prevClose": 6.01,
    "dayHigh": 6.04,
    "dayLow": 5.78,
    "volume": 3442500,
    "prevVolume": 1418000,
    "averageVolume": 2518377.777777778,
    "volumeChange": 142.77,
    "volumeVsAvg": 36.7,
    "recentVolumes": [
      1984200,
      1806900,
      1585000,
      1418000,
      3442500
    ],
    "marketCap": 1657425792,
    "fiftyTwoWeekHigh": 7.63,
    "fiftyTwoWeekLow": 3.17,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "MannKind Expands Executive Leadership Team",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-06 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mannkind-expands-executive-leadership-team-213000703.html"
      },
      {
        "title": "Here\u2019s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-06 05:47:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-mannkind-corporation-nasdaq-mnkd-134743954.html"
      },
      {
        "title": "Exploring 3 High Growth Tech Stocks In The United States",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-23 06:06:50",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-140650910.html"
      },
      {
        "title": "MannKind Shares Rise After Wells Fargo Begins Coverage",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 11:24:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mannkind-shares-rise-wells-fargo-192406328.html"
      },
      {
        "title": "Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 04:55:30",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wells-fargo-initiates-coverage-mannkind-125530032.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "XERS",
    "timestamp": "2025-01-20 18:12:56",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.19,
    "priceChange": -0.93,
    "openPrice": 3.24,
    "prevClose": 3.22,
    "dayHigh": 3.26,
    "dayLow": 3.15,
    "volume": 892700,
    "prevVolume": 983400,
    "averageVolume": 1573774.4444444445,
    "volumeChange": -9.22,
    "volumeVsAvg": -43.28,
    "recentVolumes": [
      1838900,
      1114000,
      1322000,
      983400,
      892700
    ],
    "marketCap": 477059168,
    "fiftyTwoWeekHigh": 3.87,
    "fiftyTwoWeekLow": 1.69,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M",
        "publisher": "TipRanks",
        "timestamp": "2025-01-11 04:27:32",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-biopharma-raises-fy24-revenue-122732552.html"
      },
      {
        "title": "Xeris Biopharma Lifts 2024 Revenue Guidance",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 06:44:38",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-biopharma-lifts-2024-revenue-144438633.html"
      },
      {
        "title": "Xeris Expects to Exceed Full-Year 2024 Financial Guidance",
        "publisher": "Business Wire",
        "timestamp": "2025-01-10 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-expects-exceed-full-2024-120000081.html"
      },
      {
        "title": "Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",
        "publisher": "Business Wire",
        "timestamp": "2025-01-06 13:15:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-announces-inducement-grants-under-211500652.html"
      },
      {
        "title": "Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference",
        "publisher": "Business Wire",
        "timestamp": "2024-11-26 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/xeris-participate-piper-sandler-36th-120000879.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SNDX",
    "timestamp": "2025-01-20 18:12:57",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 13.08,
    "priceChange": 0.62,
    "openPrice": 13.17,
    "prevClose": 13.0,
    "dayHigh": 13.22,
    "dayLow": 12.94,
    "volume": 1136100,
    "prevVolume": 1460000,
    "averageVolume": 1804760.0,
    "volumeChange": -22.18,
    "volumeVsAvg": -37.05,
    "recentVolumes": [
      1521300,
      2121900,
      1479000,
      1460000,
      1136100
    ],
    "marketCap": 1116478720,
    "fiftyTwoWeekHigh": 25.34,
    "fiftyTwoWeekLow": 12.06,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-16 03:29:17",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/incyte-syndax-receive-fda-approval-112917184.html"
      },
      {
        "title": "Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo\u2122 (axatilimab-csfr) 9 mg and 22 mg Vial Sizes",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-15 14:34:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/incyte-syndax-announce-u-food-223400628.html"
      },
      {
        "title": "Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syndax-highlights-recent-accomplishments-anticipated-120000027.html"
      },
      {
        "title": "Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-10 06:16:04",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/investing-syndax-pharmaceuticals-nasdaq-sndx-141604837.html"
      },
      {
        "title": "Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "PR Newswire",
        "timestamp": "2025-01-07 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/syndax-announces-presentation-43rd-annual-120000082.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "PLRX",
    "timestamp": "2025-01-20 18:13:00",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 11.21,
    "priceChange": -3.36,
    "openPrice": 11.65,
    "prevClose": 11.6,
    "dayHigh": 11.73,
    "dayLow": 10.94,
    "volume": 672600,
    "prevVolume": 415700,
    "averageVolume": 478277.77777777775,
    "volumeChange": 61.8,
    "volumeVsAvg": 40.63,
    "recentVolumes": [
      405700,
      380000,
      533900,
      415700,
      672600
    ],
    "marketCap": 682168832,
    "fiftyTwoWeekHigh": 18.92,
    "fiftyTwoWeekLow": 10.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-02 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-participate-43rd-annual-130000646.html"
      },
      {
        "title": "Pliant Therapeutics to Participate in Upcoming Investor Events",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-21 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-participate-upcoming-investor-130000606.html"
      },
      {
        "title": "Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting\u00ae 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-18 15:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-presents-data-bexotegrast-230000838.html"
      },
      {
        "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-provides-corporate-reports-210500264.html"
      },
      {
        "title": "Pliant Therapeutics to Participate in the Stifel Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-06 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/pliant-therapeutics-participate-stifel-healthcare-130000876.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MREO",
    "timestamp": "2025-01-20 18:13:01",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.86,
    "priceChange": -1.52,
    "openPrice": 2.89,
    "prevClose": 2.9,
    "dayHigh": 2.93,
    "dayLow": 2.8,
    "volume": 1166900,
    "prevVolume": 1921000,
    "averageVolume": 890304.4444444445,
    "volumeChange": -39.26,
    "volumeVsAvg": 31.07,
    "recentVolumes": [
      2557500,
      2322900,
      1135500,
      1921000,
      1166900
    ],
    "marketCap": 443717536,
    "fiftyTwoWeekHigh": 5.02,
    "fiftyTwoWeekLow": 2.52,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Mereo BioPharma Provides Update on Lead Clinical Programs",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-12 08:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-provides-lead-clinical-160500563.html"
      },
      {
        "title": "Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-07 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-present-43rd-annual-123000624.html"
      },
      {
        "title": "Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now?",
        "publisher": "Insider Monkey",
        "timestamp": "2024-12-30 11:50:47",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-mereo-biopharma-mreo-one-195047280.html"
      },
      {
        "title": "Mereo BioPharma initiated with a Buy at Jefferies",
        "publisher": "TipRanks",
        "timestamp": "2024-12-07 02:20:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-initiated-buy-jefferies-102008990.html"
      },
      {
        "title": "Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89%",
        "publisher": "GuruFocus.com",
        "timestamp": "2024-12-06 10:18:36",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mereo-biopharma-stock-climbs-following-181836226.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MDGL",
    "timestamp": "2025-01-20 18:13:02",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 293.36,
    "priceChange": 7.54,
    "openPrice": 273.61,
    "prevClose": 272.79,
    "dayHigh": 301.44,
    "dayLow": 270.51,
    "volume": 864400,
    "prevVolume": 384900,
    "averageVolume": 400086.6666666667,
    "volumeChange": 124.58,
    "volumeVsAvg": 116.05,
    "recentVolumes": [
      1009200,
      576700,
      768700,
      384900,
      864400
    ],
    "marketCap": 6404406272,
    "fiftyTwoWeekHigh": 368.29,
    "fiftyTwoWeekLow": 168.25,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Why Madrigal Pharmaceuticals Stock Was Plummeting This Week",
        "publisher": "Motley Fool",
        "timestamp": "2025-01-17 05:28:37",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/362af982-c807-34a8-9bee-081e745c241b/why-madrigal-pharmaceuticals.html"
      },
      {
        "title": "MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 06:41:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mdgl-stock-down-10-disappointing-144100165.html"
      },
      {
        "title": "Update: Madrigal Pharmaceuticals Shares Decline After Posting Preliminary Q4 Rezdiffra Net Sales of Up to $103 Million",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-13 09:19:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-shares-decline-posting-171906061.html"
      },
      {
        "title": "Why Madrigal Pharmaceuticals Stock Is Sinking Today",
        "publisher": "Motley Fool",
        "timestamp": "2025-01-13 08:20:25",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/f71ac8aa-6b59-3f4d-836b-b2d11f9ecb61/why-madrigal-pharmaceuticals.html"
      },
      {
        "title": "Madrigal Pharmaceuticals Reports Preliminary Q4 Rezdiffra Net Sales of Up to $103 Million",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-13 05:26:34",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-reports-preliminary-q4-132634562.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 5,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "KZR",
    "timestamp": "2025-01-20 18:13:02",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 6.16,
    "priceChange": -2.84,
    "openPrice": 6.25,
    "prevClose": 6.34,
    "dayHigh": 6.63,
    "dayLow": 6.16,
    "volume": 110300,
    "prevVolume": 35400,
    "averageVolume": 87534.11111111111,
    "volumeChange": 211.58,
    "volumeVsAvg": 26.01,
    "recentVolumes": [
      58500,
      56400,
      53500,
      35400,
      110300
    ],
    "marketCap": 45163604,
    "fiftyTwoWeekHigh": 11.4,
    "fiftyTwoWeekLow": 5.2,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Kezar struck again with second FDA hold",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2024-11-13 09:30:44",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/cdcea067-689e-3f71-b98d-620d901d10b5/kezar-struck-again-with.html"
      },
      {
        "title": "Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update",
        "publisher": "Business Wire",
        "timestamp": "2024-11-12 13:01:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/kezar-life-sciences-reports-third-210100311.html"
      },
      {
        "title": "Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split",
        "publisher": "MT Newswires",
        "timestamp": "2024-10-28 07:35:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/kezar-life-sciences-implement-1-143549200.html"
      },
      {
        "title": "Kezar Life Sciences Announces 1-for-10 Reverse Stock Split",
        "publisher": "Business Wire",
        "timestamp": "2024-10-28 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/kezar-life-sciences-announces-1-123000891.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GALT",
    "timestamp": "2025-01-20 18:13:03",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.24,
    "priceChange": -0.8,
    "openPrice": 1.25,
    "prevClose": 1.25,
    "dayHigh": 1.28,
    "dayLow": 1.21,
    "volume": 229500,
    "prevVolume": 172400,
    "averageVolume": 525896.6666666666,
    "volumeChange": 33.12,
    "volumeVsAvg": -56.36,
    "recentVolumes": [
      326100,
      261300,
      312900,
      172400,
      229500
    ],
    "marketCap": 77824632,
    "fiftyTwoWeekHigh": 4.27,
    "fiftyTwoWeekLow": 0.73,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Galectin Therapeutics to Present at the 2025 MASH-TAG Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-10 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galectin-therapeutics-present-2025-mash-130000482.html"
      },
      {
        "title": "Top Midday Decliners",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 11:16:28",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/top-midday-decliners-191628936.html"
      },
      {
        "title": "Galectin's Belapectin Study Shows Mixed Endpoint Results; Shares Fall Pre-Bell",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-20 06:10:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galectin-apos-belapectin-study-shows-141002440.html"
      },
      {
        "title": "Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-20 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/galectin-therapeutics-announces-top-line-130000165.html"
      },
      {
        "title": "Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks",
        "publisher": "Zacks",
        "timestamp": "2024-12-09 06:35:06",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/heres-why-galectin-therapeutics-galt-143506667.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ETNB",
    "timestamp": "2025-01-20 18:13:03",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 6.3,
    "priceChange": 3.45,
    "openPrice": 6.18,
    "prevClose": 6.09,
    "dayHigh": 6.32,
    "dayLow": 6.08,
    "volume": 1863200,
    "prevVolume": 1329500,
    "averageVolume": 887175.5555555555,
    "volumeChange": 40.14,
    "volumeVsAvg": 110.01,
    "recentVolumes": [
      1142700,
      871200,
      967200,
      1329500,
      1863200
    ],
    "marketCap": 741942400,
    "fiftyTwoWeekHigh": 16.63,
    "fiftyTwoWeekLow": 5.99,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "89bio Provides Business Update and Outlook for 2025",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-provides-business-outlook-2025-130000542.html"
      },
      {
        "title": "New Strong Sell Stocks for January 7th",
        "publisher": "Zacks",
        "timestamp": "2025-01-07 00:17:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/strong-sell-stocks-january-7th-081700612.html"
      },
      {
        "title": "89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-19 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-announces-inducement-grants-under-210500686.html"
      },
      {
        "title": "Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?",
        "publisher": "Insider Monkey",
        "timestamp": "2024-12-04 10:02:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-89bio-inc-etnb-among-180208816.html"
      },
      {
        "title": "89bio to Participate in the 7th Annual Evercore HealthCONx Conference",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-26 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/89bio-participate-7th-annual-evercore-210500008.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CMRX",
    "timestamp": "2025-01-20 18:13:06",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.55,
    "priceChange": -3.01,
    "openPrice": 3.58,
    "prevClose": 3.66,
    "dayHigh": 3.67,
    "dayLow": 3.54,
    "volume": 927100,
    "prevVolume": 1138800,
    "averageVolume": 2986061.111111111,
    "volumeChange": -18.59,
    "volumeVsAvg": -68.95,
    "recentVolumes": [
      1444700,
      2358600,
      1788400,
      1138800,
      927100
    ],
    "marketCap": 319405568,
    "fiftyTwoWeekHigh": 3.8,
    "fiftyTwoWeekLow": 0.75,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "US Penny Stocks To Watch In January 2025",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-16 16:05:01",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/us-penny-stocks-watch-january-000501342.html"
      },
      {
        "title": "Here\u2019s Why Chimerix, Inc. (CMRX) Is Skyrocketing",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-13 13:21:53",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-chimerix-inc-cmrx-skyrocketing-212153927.html"
      },
      {
        "title": "Chimerix to Speak Today at The White House Cancer Moonshot Forum",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chimerix-speak-today-white-house-120000327.html"
      },
      {
        "title": "Chimerix Seeks Accelerated FDA Approval for Experimental Tumor Drug",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-30 04:26:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chimerix-seeks-accelerated-fda-approval-122643275.html"
      },
      {
        "title": "Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-30 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/chimerix-submits-dordaviprone-drug-application-120000746.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "CDTX",
    "timestamp": "2025-01-20 18:13:06",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 21.77,
    "priceChange": 2.45,
    "openPrice": 21.04,
    "prevClose": 21.25,
    "dayHigh": 22.0,
    "dayLow": 20.76,
    "volume": 229200,
    "prevVolume": 113500,
    "averageVolume": 58418.88888888889,
    "volumeChange": 101.94,
    "volumeVsAvg": 292.34,
    "recentVolumes": [
      95100,
      74800,
      93200,
      113500,
      229200
    ],
    "marketCap": 237510848,
    "fiftyTwoWeekHigh": 28.42,
    "fiftyTwoWeekLow": 10.0,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Here\u2019s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-13 12:37:47",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-cidara-therapeutics-inc-cdtx-203747448.html"
      },
      {
        "title": "Cidara Therapeutics Files Secondary Stock Sale Statement",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-23 14:31:02",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cidara-therapeutics-files-secondary-stock-223102693.html"
      },
      {
        "title": "RBC Initiates Cidara Therapeutics at Outperform, Speculative Risk, With $34 Price Target",
        "publisher": "MT Newswires",
        "timestamp": "2024-12-13 03:24:01",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rbc-initiates-cidara-therapeutics-outperform-112401932.html"
      },
      {
        "title": "Cidara achieves full enrolment in influenza prevention trial",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2024-12-05 08:07:21",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/89358c44-d90a-3a71-94f0-cd68f618006e/cidara-achieves-full.html"
      },
      {
        "title": "Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-04 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/cidara-therapeutics-completes-enrollment-phase-130000598.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "GYRE",
    "timestamp": "2025-01-20 18:13:07",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 10.95,
    "priceChange": 1.39,
    "openPrice": 10.69,
    "prevClose": 10.8,
    "dayHigh": 10.95,
    "dayLow": 10.58,
    "volume": 49000,
    "prevVolume": 78200,
    "averageVolume": 88688.88888888889,
    "volumeChange": -37.34,
    "volumeVsAvg": -44.75,
    "recentVolumes": [
      114000,
      105900,
      89100,
      78200,
      49000
    ],
    "marketCap": 939754240,
    "fiftyTwoWeekHigh": 26.37,
    "fiftyTwoWeekLow": 8.26,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-06 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-announces-appointment-ping-120000756.html"
      },
      {
        "title": "Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-15 03:27:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-third-quarter-2024-112712072.html"
      },
      {
        "title": "Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-13 03:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/gyre-therapeutics-reports-third-quarter-110000878.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "AGEN",
    "timestamp": "2025-01-20 18:13:10",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.48,
    "priceChange": 10.48,
    "openPrice": 3.23,
    "prevClose": 3.15,
    "dayHigh": 3.5,
    "dayLow": 3.17,
    "volume": 377800,
    "prevVolume": 151900,
    "averageVolume": 465234.44444444444,
    "volumeChange": 148.72,
    "volumeVsAvg": -18.79,
    "recentVolumes": [
      159900,
      300200,
      272600,
      151900,
      377800
    ],
    "marketCap": 82169416,
    "fiftyTwoWeekHigh": 19.69,
    "fiftyTwoWeekLow": 2.5,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "What Makes Agenus (AGEN) a New Buy Stock",
        "publisher": "Zacks",
        "timestamp": "2025-01-20 09:00:12",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/makes-agenus-agen-buy-stock-170012733.html"
      },
      {
        "title": "Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?",
        "publisher": "Zacks",
        "timestamp": "2025-01-20 06:40:08",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/agenus-agen-stock-outpacing-medical-144008291.html"
      },
      {
        "title": "Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers",
        "publisher": "Business Wire",
        "timestamp": "2024-12-18 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/agenus-announces-five-presentations-asco-123000509.html"
      },
      {
        "title": "AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B",
        "publisher": "BioPharma Dive",
        "timestamp": "2024-12-06 03:07:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/f2886d5f-a566-3990-9852-ec8793fba968/astrazeneca%2C-daiichi-build.html"
      },
      {
        "title": "Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs",
        "publisher": "Business Wire",
        "timestamp": "2024-12-05 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/agenus-announces-strategic-realignment-focus-123000921.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ABUS",
    "timestamp": "2025-01-20 18:13:10",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 3.19,
    "priceChange": -0.93,
    "openPrice": 3.23,
    "prevClose": 3.22,
    "dayHigh": 3.24,
    "dayLow": 3.17,
    "volume": 609900,
    "prevVolume": 721300,
    "averageVolume": 985184.4444444445,
    "volumeChange": -15.44,
    "volumeVsAvg": -38.09,
    "recentVolumes": [
      1059300,
      751100,
      716200,
      721300,
      609900
    ],
    "marketCap": 606374400,
    "fiftyTwoWeekHigh": 4.72,
    "fiftyTwoWeekLow": 2.27,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Jim Cramer on\u00a0Arbutus Biopharma Corporation (ABUS): \u2018It Loses Money\u2019",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-16 08:22:43",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/jim-cramer-arbutus-biopharma-corporation-162243863.html"
      },
      {
        "title": "Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?",
        "publisher": "Zacks",
        "timestamp": "2025-01-15 06:38:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/kymera-therapeutics-kymr-moves-7-143800359.html"
      },
      {
        "title": "Arbutus Provides 2025 Corporate and Financial Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 04:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/arbutus-provides-2025-corporate-financial-123000233.html"
      },
      {
        "title": "Here\u2019s Why Arbutus (ABUS) Surged in Q3",
        "publisher": "Insider Monkey",
        "timestamp": "2024-12-06 05:20:23",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-arbutus-abus-surged-q3-132023599.html"
      },
      {
        "title": "Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors",
        "publisher": "Business Wire",
        "timestamp": "2024-12-03 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/whitefort-capital-sends-letter-arbutus-130000141.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ABCL",
    "timestamp": "2025-01-20 18:13:11",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 2.97,
    "priceChange": 1.02,
    "openPrice": 2.95,
    "prevClose": 2.94,
    "dayHigh": 3.0,
    "dayLow": 2.92,
    "volume": 1566300,
    "prevVolume": 2994300,
    "averageVolume": 2451013.3333333335,
    "volumeChange": -47.69,
    "volumeVsAvg": -36.1,
    "recentVolumes": [
      4142700,
      5688500,
      4444800,
      2994300,
      1566300
    ],
    "marketCap": 877237056,
    "fiftyTwoWeekHigh": 5.62,
    "fiftyTwoWeekLow": 2.33,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%",
        "publisher": "Simply Wall St.",
        "timestamp": "2025-01-20 06:00:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-biologics-inc-nasdaq-abcl-140056068.html"
      },
      {
        "title": "AbCellera Biologics Inc. (ABCL): A Bull Case Theory",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-17 04:53:55",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-bull-125355594.html"
      },
      {
        "title": "AbbVie and Simcere Zaiming link to develop trispecific antibody",
        "publisher": "Pharmaceutical Technology",
        "timestamp": "2025-01-15 07:47:40",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/cf055efb-38f2-3dc2-a7e7-dbfb0c290df9/abbvie-and-simcere-zaiming.html"
      },
      {
        "title": "AbCellera expands collaboration with AbbVie",
        "publisher": "TipRanks",
        "timestamp": "2025-01-14 06:25:57",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-expands-collaboration-abbvie-142557828.html"
      },
      {
        "title": "AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology",
        "publisher": "Business Wire",
        "timestamp": "2025-01-13 06:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abcellera-expands-collaboration-abbvie-develop-140000136.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "LOGC",
    "timestamp": "2025-01-20 18:13:12",
    "sector": "Consumer Cyclical",
    "industry": "Internet Retail",
    "price": 6.87,
    "priceChange": 1.93,
    "openPrice": 6.82,
    "prevClose": 6.74,
    "dayHigh": 6.97,
    "dayLow": 6.7,
    "volume": 198600,
    "prevVolume": 108000,
    "averageVolume": 260498.88888888888,
    "volumeChange": 83.89,
    "volumeVsAvg": -23.76,
    "recentVolumes": [
      126400,
      176400,
      146400,
      108000,
      198600
    ],
    "marketCap": 180578640,
    "fiftyTwoWeekHigh": 8.24,
    "fiftyTwoWeekLow": 4.13,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "ContextLogic Inc. (NASDAQ:LOGC): Is Breakeven Near?",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-12-20 02:20:28",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/contextlogic-inc-nasdaq-logc-breakeven-102028599.html"
      },
      {
        "title": "ContextLogic Third Quarter 2024 Earnings: US$0.038 loss per share (vs US$3.35 loss in 3Q 2023)",
        "publisher": "Simply Wall St.",
        "timestamp": "2024-11-09 06:00:26",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/contextlogic-third-quarter-2024-earnings-140026710.html"
      },
      {
        "title": "ContextLogic Inc. Reports Third-Quarter 2024 Financial Results",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-07 13:10:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/contextlogic-inc-reports-third-quarter-211000733.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ADVM",
    "timestamp": "2025-01-20 18:13:15",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 4.33,
    "priceChange": 0.93,
    "openPrice": 4.33,
    "prevClose": 4.29,
    "dayHigh": 4.38,
    "dayLow": 4.22,
    "volume": 120400,
    "prevVolume": 176200,
    "averageVolume": 220852.22222222222,
    "volumeChange": -31.67,
    "volumeVsAvg": -45.48,
    "recentVolumes": [
      206500,
      313900,
      275900,
      176200,
      120400
    ],
    "marketCap": 90074824,
    "fiftyTwoWeekHigh": 29.7,
    "fiftyTwoWeekLow": 4.01,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-06 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-reports-inducement-grants-210500881.html"
      },
      {
        "title": "Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-22 10:28:49",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mizuho-securities-cuts-price-target-182849930.html"
      },
      {
        "title": "Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-20 13:05:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-reports-inducement-grant-210500959.html"
      },
      {
        "title": "Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell",
        "publisher": "MT Newswires",
        "timestamp": "2024-11-18 05:16:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-reports-positive-ixo-vec-131656175.html"
      },
      {
        "title": "Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-11-18 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adverum-biotechnologies-announces-positive-52-120000226.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "SNY",
    "timestamp": "2025-01-20 18:13:15",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 50.73,
    "priceChange": -0.02,
    "openPrice": 50.78,
    "prevClose": 50.74,
    "dayHigh": 51.05,
    "dayLow": 50.46,
    "volume": 2426200,
    "prevVolume": 5171100,
    "averageVolume": 2176785.5555555555,
    "volumeChange": -53.08,
    "volumeVsAvg": 11.46,
    "recentVolumes": [
      2001200,
      1680800,
      2345000,
      5171100,
      2426200
    ],
    "marketCap": 127214321664,
    "fiftyTwoWeekHigh": 58.97,
    "fiftyTwoWeekLow": 45.22,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "SK bioscience and Sanofi\u2019s GBP410 vaccine enters global Phase III trials",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2025-01-20 09:59:35",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/c041806e-0787-3d13-a541-d0ecae0c361b/sk-bioscience-and-sanofi%E2%80%99s.html"
      },
      {
        "title": "Sanofi to increase competition in atopic dermatitis market after Dupixent success",
        "publisher": "Clinical Trials Arena",
        "timestamp": "2025-01-16 05:25:40",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/7631a92a-251c-319a-bcbc-2138a90b6c0f/sanofi-to-increase.html"
      },
      {
        "title": "Sanofi: Information concerning the total number of voting rights and shares \u2013 November 2024",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-15 09:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/sanofi-information-concerning-total-number-173000556.html"
      },
      {
        "title": "SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 01:16:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/snys-subcutaneous-sarclisa-proves-non-091600551.html"
      },
      {
        "title": "Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-12 22:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/press-release-sarclisa-obtains-first-060000248.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "MRSN",
    "timestamp": "2025-01-20 18:13:16",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 0.62,
    "priceChange": 1.38,
    "openPrice": 0.6,
    "prevClose": 0.61,
    "dayHigh": 0.63,
    "dayLow": 0.58,
    "volume": 7695900,
    "prevVolume": 13218200,
    "averageVolume": 2444740.0,
    "volumeChange": -41.78,
    "volumeVsAvg": 214.79,
    "recentVolumes": [
      19183200,
      9675000,
      7971600,
      13218200,
      7695900
    ],
    "marketCap": 76417512,
    "fiftyTwoWeekHigh": 6.28,
    "fiftyTwoWeekLow": 0.56,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 10:01:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/wedbush-cuts-price-target-mersana-180156781.html"
      },
      {
        "title": "Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?",
        "publisher": "Benzinga",
        "timestamp": "2025-01-10 09:49:37",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-cancer-focused-mersana-therapeutics-174937358.html"
      },
      {
        "title": "Mersana Therapeutics' XMT-1660 Gains Additional US FDA Fast Track Designation",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 03:58:23",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mersana-therapeutics-apos-xmt-1660-115823578.html"
      },
      {
        "title": "Mersana Therapeutics Says Initial Data From Cancer Drug Trial Shows Promise, Shares Rise Premarket",
        "publisher": "MT Newswires",
        "timestamp": "2025-01-10 03:37:14",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mersana-therapeutics-says-initial-data-113714609.html"
      },
      {
        "title": "Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted\u00a0to Emiltatug Ledadotin (XMT-1660)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-10 03:02:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/mersana-therapeutics-announces-additional-fda-110200438.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "TCRT",
    "timestamp": "2025-01-20 18:13:16",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 1.8,
    "priceChange": 4.05,
    "openPrice": 1.73,
    "prevClose": 1.73,
    "dayHigh": 1.8,
    "dayLow": 1.7,
    "volume": 19000,
    "prevVolume": 13800,
    "averageVolume": 24533.333333333332,
    "volumeChange": 37.68,
    "volumeVsAvg": -22.55,
    "recentVolumes": [
      21800,
      6000,
      7800,
      13800,
      19000
    ],
    "marketCap": 2882250,
    "fiftyTwoWeekHigh": 33.0,
    "fiftyTwoWeekLow": 1.63,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": false
    }
  },
  {
    "symbol": "ASRT",
    "timestamp": "2025-01-20 18:13:17",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "price": 0.83,
    "priceChange": 3.47,
    "openPrice": 0.81,
    "prevClose": 0.8,
    "dayHigh": 0.85,
    "dayLow": 0.8,
    "volume": 434500,
    "prevVolume": 187000,
    "averageVolume": 674845.5555555555,
    "volumeChange": 132.35,
    "volumeVsAvg": -35.61,
    "recentVolumes": [
      449800,
      752000,
      290500,
      187000,
      434500
    ],
    "marketCap": 78988784,
    "fiftyTwoWeekHigh": 1.8,
    "fiftyTwoWeekLow": 0.73,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-03 13:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-holdings-inc-reports-inducement-213000113.html"
      },
      {
        "title": "Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-17 05:30:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-holdings-inc-appoints-mark-133000116.html"
      },
      {
        "title": "Assertio Announces Results of Rolvedon\u00ae (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-13 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-announces-results-rolvedon-eflapegrastim-130000327.html"
      },
      {
        "title": "Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-12 05:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/assertio-holdings-inc-appoints-paul-130000086.html"
      },
      {
        "title": "Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer",
        "publisher": "GlobeNewswire",
        "timestamp": "2024-12-06 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/beam-therapeutics-announces-appointment-sravan-120000274.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ABBV",
    "timestamp": "2025-01-20 18:13:18",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "price": 171.48,
    "priceChange": -1.28,
    "openPrice": 172.88,
    "prevClose": 173.7,
    "dayHigh": 173.99,
    "dayLow": 171.27,
    "volume": 7816400,
    "prevVolume": 5236000,
    "averageVolume": 5841851.111111111,
    "volumeChange": 49.28,
    "volumeVsAvg": 33.8,
    "recentVolumes": [
      4734100,
      4779100,
      8048700,
      5236000,
      7816400
    ],
    "marketCap": 303170519040,
    "fiftyTwoWeekHigh": 207.32,
    "fiftyTwoWeekLow": 153.58,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "AbbVie Inc. (ABBV): A Bull Case Theory",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-20 04:50:36",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-bull-case-125036173.html"
      },
      {
        "title": "Top Wall Street Analyst Says Dump The Magnificent 7 And Go All In On These Three Big Pharma Dividend Stocks",
        "publisher": "Benzinga",
        "timestamp": "2025-01-19 09:01:03",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/top-wall-street-analyst-says-170103097.html"
      },
      {
        "title": "Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market",
        "publisher": "TipRanks",
        "timestamp": "2025-01-18 14:01:19",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/count-dividend-king-pepsi-pep-220119889.html"
      },
      {
        "title": "Why Is AbbVie Inc. (ABBV) Among Louis Navellier\u2019s Top Long-term Stock Picks?",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-18 08:21:57",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/why-abbvie-inc-abbv-among-162157052.html"
      },
      {
        "title": "Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",
        "publisher": "TipRanks",
        "timestamp": "2025-01-18 05:20:48",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/ozempic-xtandi-among-next-15-132048211.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "ADMA",
    "timestamp": "2025-01-20 18:13:18",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "price": 16.01,
    "priceChange": -3.7,
    "openPrice": 16.77,
    "prevClose": 16.63,
    "dayHigh": 16.86,
    "dayLow": 15.98,
    "volume": 3054100,
    "prevVolume": 1928300,
    "averageVolume": 4252595.555555556,
    "volumeChange": 58.38,
    "volumeVsAvg": -28.18,
    "recentVolumes": [
      4031300,
      2710800,
      2727700,
      1928300,
      3054100
    ],
    "marketCap": 3786967808,
    "fiftyTwoWeekHigh": 23.64,
    "fiftyTwoWeekLow": 5.02,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "ADMA Biologics Inc. (ADMA): Why Should You Buy This Growth Stock For The Next 5 Years?",
        "publisher": "Insider Monkey",
        "timestamp": "2025-01-18 11:01:56",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adma-biologics-inc-adma-why-190156576.html"
      },
      {
        "title": "Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why",
        "publisher": "Zacks",
        "timestamp": "2025-01-14 14:50:20",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adma-biologics-adma-stock-sinks-225020171.html"
      },
      {
        "title": "ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update",
        "publisher": "GlobeNewswire",
        "timestamp": "2025-01-13 04:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adma-biologics-announces-preliminary-full-120000619.html"
      },
      {
        "title": "The Top Stock Funds of 2024",
        "publisher": "The Wall Street Journal",
        "timestamp": "2025-01-11 07:00:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/m/ea52e47d-43cc-3b0a-b338-e0175a8b45a0/the-top-stock-funds-of-2024.html"
      },
      {
        "title": "ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?",
        "publisher": "Zacks",
        "timestamp": "2025-01-10 10:41:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/adma-stock-catapults-275-7-184100433.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  },
  {
    "symbol": "RKLB",
    "timestamp": "2025-01-20 18:13:19",
    "sector": "Industrials",
    "industry": "Aerospace & Defense",
    "price": 24.0,
    "priceChange": -2.6,
    "openPrice": 25.1,
    "prevClose": 24.64,
    "dayHigh": 25.65,
    "dayLow": 23.95,
    "volume": 14034000,
    "prevVolume": 10860200,
    "averageVolume": 19031276.666666668,
    "volumeChange": 29.22,
    "volumeVsAvg": -26.26,
    "recentVolumes": [
      18040200,
      13862800,
      15252200,
      10860200,
      14034000
    ],
    "marketCap": 10775040000,
    "fiftyTwoWeekHigh": 30.26,
    "fiftyTwoWeekLow": 3.47,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": []
    },
    "recentNews": [
      {
        "title": "SpaceX's Starship explodes mid-air after Texas launch",
        "publisher": "Yahoo Finance Video",
        "timestamp": "2025-01-17 08:40:00",
        "type": "VIDEO",
        "url": "https://finance.yahoo.com/video/spacexs-starship-explodes-mid-air-164000978.html"
      },
      {
        "title": "Blue Origin's New Glenn rocket reaches orbit in test flight",
        "publisher": "Yahoo Finance Video",
        "timestamp": "2025-01-16 08:02:25",
        "type": "VIDEO",
        "url": "https://finance.yahoo.com/video/blue-origins-glenn-rocket-reaches-160225707.html"
      },
      {
        "title": "Rocket Lab\u2019s Second Reentry Class Spacecraft for Varda Operating on Orbit Supporting Payloads for Air Force Research Lab and NASA",
        "publisher": "Business Wire",
        "timestamp": "2025-01-15 15:46:00",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rocket-lab-second-reentry-class-234600551.html"
      },
      {
        "title": "Rocket Lab to Provide Neutron Launch Services for NASA Under VADR Contract",
        "publisher": "GuruFocus.com",
        "timestamp": "2025-01-10 09:29:52",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rocket-lab-neutron-launch-services-172952963.html"
      },
      {
        "title": "Rocket Lab Expands NASA Partnership with Neutron Rocket Integration",
        "publisher": "GuruFocus.com",
        "timestamp": "2025-01-10 09:24:57",
        "type": "STORY",
        "url": "https://finance.yahoo.com/news/rocket-lab-expands-nasa-partnership-172457663.html"
      }
    ],
    "analystRating": {
      "rating": "N/A",
      "firm": "N/A",
      "date": "N/A"
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true
    }
  }
]